785bfcf1 personal page - To The Moon

785bfcf1

No personal profile

56Follow

19Followers

0Topic

0Badge

2021-09-23

$Ford(F)$reset position ?

2021-09-22

2021-09-22

$NIO Inc.(NIO)$its time to enter

2021-09-22

$Marin(MRIN)$tought will be dropped once market open later, let's see. If not then I'll book the ticket too.

2021-09-22

Up up up

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

2021-09-21

$Farmmi, Inc.(FAMI)$amazing, downtrend, low price but high volume.

2021-09-19

Like

Ford wakes up badly burnt from its India dream

2021-09-16

$Camber Energy(CEI)$left pocket to right pocket... Just watching the show.

2021-09-15

Hmmm

Wall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.

2021-09-14

Hmmmm

Why SmileDirectClub Shares Surged Higher Today

2021-09-11

Let's see Oct 1.

BBIG Stock: 10 Things to Know About Reddit Favorite and Short-Squeeze Target Vinco Ventures

2021-09-10

Means good time to buy now before skyrocketing next year, ok I'll buy. Investment in dip not when is exploded.

Apple's satellite iPhone features to focus on emergencies only

2021-09-09

Hmmmm

Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins

2021-09-08

Pls decrease more then more people will buy it

Sorry, the original content has been removed

2021-09-04

$Exela Technologies, Inc.(XELA)$up trending still continuous for this week

2021-09-04

Study's speed should be faster than up and down candlesticks

Here's Why Skillz Stock Suddenly Spiked Today

2021-09-03

$Exela Technologies, Inc.(XELA)$like a coin that have two sides either long or short, it's depend on you how to anticipate...

2021-08-30

$Pfizer(PFE)$great job!!!

2021-08-26

Hmmmm

Express Inc Stock Gains After Q2 Earnings Beat

2021-08-24

$Palantir Technologies Inc.(PLTR)$cmon up up

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3586474323146945,"uuid":"3586474323146945","gmtCreate":1623383485295,"gmtModify":1627545406437,"name":"785bfcf1","pinyin":"785bfcf1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":19,"headSize":56,"tweetSize":89,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":863962623,"gmtCreate":1632353968962,"gmtModify":1676530759078,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>reset position ?","listText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>reset position ?","text":"$Ford(F)$reset position ?","images":[{"img":"https://static.tigerbbs.com/52d069c1adf9568c246b758c73422a91","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863962623","isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869760681,"gmtCreate":1632322353943,"gmtModify":1676530753055,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>7","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>7","text":"$Marin(MRIN)$7","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869760681","isVote":1,"tweetType":1,"viewCount":665,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869799156,"gmtCreate":1632320411675,"gmtModify":1676530752049,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>its time to enter","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>its time to enter","text":"$NIO Inc.(NIO)$its time to enter","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869799156","isVote":1,"tweetType":1,"viewCount":319,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869540802,"gmtCreate":1632309107706,"gmtModify":1676530748491,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>tought will be dropped once market open later, let's see. If not then I'll book the ticket too.","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>tought will be dropped once market open later, let's see. If not then I'll book the ticket too.","text":"$Marin(MRIN)$tought will be dropped once market open later, let's see. If not then I'll book the ticket too.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869540802","isVote":1,"tweetType":1,"viewCount":932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869505474,"gmtCreate":1632299727798,"gmtModify":1676530746477,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Up up up","listText":"Up up up","text":"Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869505474","repostId":"2169194634","repostType":2,"repost":{"id":"2169194634","pubTimestamp":1632246900,"share":"https://ttm.financial/m/news/2169194634?lang=&edition=fundamental","pubTime":"2021-09-22 01:55","market":"us","language":"en","title":"Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2169194634","media":"Business Wire","summary":"Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently t","content":"<html><body><ul>\n<li><i>Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA</i></li>\n<li><i>Participating EU/EEA countries can purchase bamlanivimab together with etesevimab directly from Lilly following national approval for emergency use or marketing authorization at the EU level</i></li>\n</ul>\n<p><b>VANCOUVER, British Columbia, September 21, 2021</b>--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. The agreement helps to provide access to treatments by enabling participating countries in the European Union (EU) and European Economic Area (EEA) to purchase the products directly from Lilly following national approval for emergency use or marketing authorization at the EU level.</p>\n<p>\"It is important that we use every tool available to combat COVID-19. With the rise of the highly contagious Delta variant, it is critical that patients who need it have access to antibody therapies that can neutralize the virus and prevent the progression to severe illness,\" said Carl Hansen, Ph.D., CEO and President of AbCellera.</p>\n<p>In the U.S., bamlanivimab alone and together with etesevimab have been used to treat more than 535,000 patients, potentially keeping more than 25,000 patients out of the hospital and saving more than 10,000 lives. The Emergency Use Authorization (EUA) for bamlanivimab together with etesevimab in the U.S. was recently expanded to include post-exposure prophylaxis to prevent COVID-19.</p>\n<p>Pseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retain neutralization activity against variants currently in circulation in many countries, including Delta and Alpha. Based on the high transmissibility of the Delta variant, currently over 95 percent of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant.</p>\n<p><b>About AbCellera’s Response to COVID-19</b></p>\n<p>AbCellera initially mobilized its pandemic response platform against COVID-19 in March of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the U.S. Food and Drug Administration (FDA). Bamlanivimab alone and together with other antibodies has treated hundreds of thousands of patients, preventing COVID-19-related hospitalizations and death.</p>\n<p>AbCellera’s ongoing efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, bebtelovimab, and other antibodies that are in various stages of testing by AbCellera and its partners.</p>\n<p>AbCellera’s pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.</p>\n<p><b>About Bamlanivimab</b></p>\n<p>Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera’s pandemic response platform, in partnership with the Vaccine Research Center (VRC) at the National Institutes for Allergy and Infectious Diseases (NIAID). Within <a href=\"https://laohu8.com/S/AONE.U\">one</a> week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies and was both the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America, and to receive Emergency Use Authorization (EUA) from the FDA. Bamlanivimab alone and/or administered with etesevimab are authorized under special use pathways in more than 22 countries. In the U.S., bamlanivimab is currently only authorized for emergency use with etesevimab.</p>\n<p>Results from a Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) were published in the <i>New England Journal of Medicine</i>. Results from a Phase 3 study of bamlanivimab in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) were published in the <i>Journal of American Medical Association</i>. A Phase 2 study assessing the efficacy and safety of bamlanivimab alone, and bamlanivimab with other neutralizing antibodies versus placebo for the treatment of symptomatic low-risk COVID-19 in the outpatient setting (BLAZE-4, NCT04634409) has completed enrollment.</p>\n<p><b>About <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc.</b></p>\n<p>AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.</p>\n<p><b>AbCellera Forward-looking Statements</b></p>\n<p>This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.</p>\n<p>In some cases, you can identify forward-looking statements by the words \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"project,\" \"potential,\" \"continue,\" \"ongoing\" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under \"Risk Factors,\" \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.</p>\n<p>Source: AbCellera Biologics Inc.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210921006004/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Inquiries</b></p>\n<p><b>Media</b>: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774<br/><b>Business Development</b>: Neil Berkley; bd@abcellera.com, +1(604)559-9005<br/><b>Investor Relations:</b> Melanie Solomon; ir@abcellera.com, +1(778)729-9116</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 01:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/lilly-supply-eu-eea-220-175500241.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA\nParticipating EU/EEA countries ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lilly-supply-eu-eea-220-175500241.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/UzFalv_go1Sfe6fYobMVaQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/lE5h6wPsvj.jqDHTIdvkbQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a2e58cf34a79b9f519b83d5ba5e534a4","relate_stocks":{"ABCL":"AbCellera Biologics"},"source_url":"https://finance.yahoo.com/news/lilly-supply-eu-eea-220-175500241.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2169194634","content_text":"Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA\nParticipating EU/EEA countries can purchase bamlanivimab together with etesevimab directly from Lilly following national approval for emergency use or marketing authorization at the EU level\n\nVANCOUVER, British Columbia, September 21, 2021--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. The agreement helps to provide access to treatments by enabling participating countries in the European Union (EU) and European Economic Area (EEA) to purchase the products directly from Lilly following national approval for emergency use or marketing authorization at the EU level.\n\"It is important that we use every tool available to combat COVID-19. With the rise of the highly contagious Delta variant, it is critical that patients who need it have access to antibody therapies that can neutralize the virus and prevent the progression to severe illness,\" said Carl Hansen, Ph.D., CEO and President of AbCellera.\nIn the U.S., bamlanivimab alone and together with etesevimab have been used to treat more than 535,000 patients, potentially keeping more than 25,000 patients out of the hospital and saving more than 10,000 lives. The Emergency Use Authorization (EUA) for bamlanivimab together with etesevimab in the U.S. was recently expanded to include post-exposure prophylaxis to prevent COVID-19.\nPseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retain neutralization activity against variants currently in circulation in many countries, including Delta and Alpha. Based on the high transmissibility of the Delta variant, currently over 95 percent of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant.\nAbout AbCellera’s Response to COVID-19\nAbCellera initially mobilized its pandemic response platform against COVID-19 in March of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the U.S. Food and Drug Administration (FDA). Bamlanivimab alone and together with other antibodies has treated hundreds of thousands of patients, preventing COVID-19-related hospitalizations and death.\nAbCellera’s ongoing efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, bebtelovimab, and other antibodies that are in various stages of testing by AbCellera and its partners.\nAbCellera’s pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.\nAbout Bamlanivimab\nBamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera’s pandemic response platform, in partnership with the Vaccine Research Center (VRC) at the National Institutes for Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies and was both the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America, and to receive Emergency Use Authorization (EUA) from the FDA. Bamlanivimab alone and/or administered with etesevimab are authorized under special use pathways in more than 22 countries. In the U.S., bamlanivimab is currently only authorized for emergency use with etesevimab.\nResults from a Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) were published in the New England Journal of Medicine. Results from a Phase 3 study of bamlanivimab in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) were published in the Journal of American Medical Association. A Phase 2 study assessing the efficacy and safety of bamlanivimab alone, and bamlanivimab with other neutralizing antibodies versus placebo for the treatment of symptomatic low-risk COVID-19 in the outpatient setting (BLAZE-4, NCT04634409) has completed enrollment.\nAbout AbCellera Biologics Inc.\nAbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.\nAbCellera Forward-looking Statements\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.\nIn some cases, you can identify forward-looking statements by the words \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"project,\" \"potential,\" \"continue,\" \"ongoing\" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under \"Risk Factors,\" \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.\nSource: AbCellera Biologics Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210921006004/en/\nContacts\nInquiries\nMedia: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774Business Development: Neil Berkley; bd@abcellera.com, +1(604)559-9005Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116","news_type":1},"isVote":1,"tweetType":1,"viewCount":476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860509825,"gmtCreate":1632185759267,"gmtModify":1676530719999,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FAMI\">$Farmmi, Inc.(FAMI)$</a>amazing, downtrend, low price but high volume.","listText":"<a href=\"https://laohu8.com/S/FAMI\">$Farmmi, Inc.(FAMI)$</a>amazing, downtrend, low price but high volume.","text":"$Farmmi, Inc.(FAMI)$amazing, downtrend, low price but high volume.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860509825","isVote":1,"tweetType":1,"viewCount":625,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581686650032769","authorId":"3581686650032769","authorIdStr":"3581686650032769","name":"Mr凡凡","avatar":"https://static.tigerbbs.com/74f90b19678878f062e15d5a34dbdc36","crmLevel":1,"crmLevelSwitch":1,"idStr":"3581686650032769"},"content":"One world , all gambler , come for quick money","text":"One world , all gambler , come for quick money","html":"One world , all gambler , come for quick money"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887820372,"gmtCreate":1632018674796,"gmtModify":1676530687228,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887820372","repostId":"2168264185","repostType":2,"repost":{"id":"2168264185","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631865384,"share":"https://ttm.financial/m/news/2168264185?lang=&edition=fundamental","pubTime":"2021-09-17 15:56","market":"us","language":"en","title":"Ford wakes up badly burnt from its India dream","url":"https://stock-news.laohu8.com/highlight/detail?id=2168264185","media":"Reuters","summary":"NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s,","content":"<p>NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s, U.S. carmakers believed they were buying into a boom - the next China.</p>\n<p>The economy had been liberalised in 1991, the government was welcoming investors, and the middle class was expected to fuel a consumption frenzy. Rising disposable income would help foreign carmakers to a market share of as much as 10%, forecasters said.</p>\n<p>It never happened.</p>\n<p>Last week, Ford took a $2 billion hit&nbsp;to stop making cars in India, following compatriots General Motors Co and Harley-Davidson Inc in closing factories in the country.</p>\n<p>Among foreigners that remain, Japan's Nissan Motor Co Ltd&nbsp;and even Germany's <a href=\"https://laohu8.com/S/VLKAF\">Volkswagen AG</a>&nbsp;- the world's biggest automaker by sales - each hold less than 1% of a car market once forecast to be the third-largest by 2020, after China and the United States, with annual sales of 5 million.</p>\n<p>Instead, sales have stagnated at about 3 million cars. The growth rate has slowed to 3.6% in the last decade versus 12% a decade earlier.</p>\n<p>Ford's retreat marks the end of an Indian dream for U.S. carmakers. It also follows its exit from Brazil announced in January reflecting an industry pivot from emerging markets to what is now widely seen as make-or-break investment in electric vehicles.</p>\n<p>Analysts and executives said foreigners badly misjudged India's potential and underestimated the complexities of operating in a vast country that rewards domestic procurement.</p>\n<p>Many failed to adapt to a preference for small, cheap, fuel-efficient cars that could bump over uneven roads without needing expensive repairs. In India, 95% of cars are priced below $20,000.</p>\n<p>Lower tax on small cars also made it harder for makers of larger cars for Western markets to compete with small-car specialists such as Japan's Suzuki Motor Corp - controlling shareholder of <a href=\"https://laohu8.com/S/MRZUY\">Maruti Suzuki India Ltd</a> , India's biggest carmaker by sales.</p>\n<p>Of foreign carmakers that invested alone in India over the past 25 years, analysts said only South Korea's Hyundai Motor Co</p>\n<p>stands out as a success, mainly due to its wide portfolio of small cars and a grasp of what Indian buyers want.</p>\n<p>\"Companies invested on the fallacy that India would have great potential and the purchasing power of buyers would go up, but the government failed to create that kind of environment and infrastructure,\" said Ravi Bhatia, president for India at JATO Dynamics, a provider of market data for the auto industry.</p>\n<p><b>EARLY MISSTEP</b></p>\n<p>Some of Ford's missteps can be traced to when it drove into India in the mid-1990s alongside Hyundai. Whereas Hyundai entered with the small, affordable \"Santro\", Ford offered the \"Escort\" saloon, first launched in Europe in the 1960s.</p>\n<p>The Escort's price shocked Indians used to Maruti Suzuki's more affordable prices, said former Ford India executive Vinay Piparsania.</p>\n<p>Ford's narrow product range also made it hard to capitalise on the appeal won by its best-selling EcoSport and Endeavour sport utility vehicles (SUVs), said analyst Ammar Master at LMC.</p>\n<p>The carmaker said it had considered bringing more models to India but determined it could not do so profitably.</p>\n<p>\"The struggle for many global brands has always been meeting India's price point because they brought global products that were developed for mature markets at a high-cost structure,\" said Master.</p>\n<p>A peculiarity of the Indian market came in mid-2000 with a lower tax rate for cars measuring less than 4 metres (13.12 ft) in length. That left Ford and rivals building India-specific sub-4 metre saloons for which sales ultimately disappointed.</p>\n<p>\"U.S. manufacturers with large truck DNAs struggled to create a good and profitable small vehicle. Nobody got the product quite right and losses piled up,\" said JATO's Bhatia.</p>\n<p><b>RISE AND FALL</b></p>\n<p>Ford had excess capacity at its first India plant when it invested $1 billion on a second in 2015. It had planned to make India an export base and raise its share of a market projected to hit 7 million cars a year by 2020 and 9 million by 2025.</p>\n<p>But the sales never followed and overall market growth stalled. Ford now utilises only about 20% of its combined annual capacity of 440,000 cars.</p>\n<p>To use its excess capacity, Ford planned to build compact cars in India for emerging markets but shelved plans</p>\n<p>in 2016 amid a global consumer preference shift to SUVs.</p>\n<p>It changed its cost structure in 2018 and the following year started work on a joint venture with local peer Mahindra &amp; Mahindra Ltd</p>\n<p>designed to reduce costs. Three years later, in December, the partners abandoned the idea</p>\n<p>After sinking $2.5 billion in India since entry and burning another $2 billion over the past decade alone, Ford decided not to invest more.</p>\n<p>\"To continue investing ... we needed to show a path for a reasonable return on investment,\" Ford India head Anurag Mehrotra told reporters last week.</p>\n<p>\"Unfortunately, we are not able to do that.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford wakes up badly burnt from its India dream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord wakes up badly burnt from its India dream\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-17 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s, U.S. carmakers believed they were buying into a boom - the next China.</p>\n<p>The economy had been liberalised in 1991, the government was welcoming investors, and the middle class was expected to fuel a consumption frenzy. Rising disposable income would help foreign carmakers to a market share of as much as 10%, forecasters said.</p>\n<p>It never happened.</p>\n<p>Last week, Ford took a $2 billion hit&nbsp;to stop making cars in India, following compatriots General Motors Co and Harley-Davidson Inc in closing factories in the country.</p>\n<p>Among foreigners that remain, Japan's Nissan Motor Co Ltd&nbsp;and even Germany's <a href=\"https://laohu8.com/S/VLKAF\">Volkswagen AG</a>&nbsp;- the world's biggest automaker by sales - each hold less than 1% of a car market once forecast to be the third-largest by 2020, after China and the United States, with annual sales of 5 million.</p>\n<p>Instead, sales have stagnated at about 3 million cars. The growth rate has slowed to 3.6% in the last decade versus 12% a decade earlier.</p>\n<p>Ford's retreat marks the end of an Indian dream for U.S. carmakers. It also follows its exit from Brazil announced in January reflecting an industry pivot from emerging markets to what is now widely seen as make-or-break investment in electric vehicles.</p>\n<p>Analysts and executives said foreigners badly misjudged India's potential and underestimated the complexities of operating in a vast country that rewards domestic procurement.</p>\n<p>Many failed to adapt to a preference for small, cheap, fuel-efficient cars that could bump over uneven roads without needing expensive repairs. In India, 95% of cars are priced below $20,000.</p>\n<p>Lower tax on small cars also made it harder for makers of larger cars for Western markets to compete with small-car specialists such as Japan's Suzuki Motor Corp - controlling shareholder of <a href=\"https://laohu8.com/S/MRZUY\">Maruti Suzuki India Ltd</a> , India's biggest carmaker by sales.</p>\n<p>Of foreign carmakers that invested alone in India over the past 25 years, analysts said only South Korea's Hyundai Motor Co</p>\n<p>stands out as a success, mainly due to its wide portfolio of small cars and a grasp of what Indian buyers want.</p>\n<p>\"Companies invested on the fallacy that India would have great potential and the purchasing power of buyers would go up, but the government failed to create that kind of environment and infrastructure,\" said Ravi Bhatia, president for India at JATO Dynamics, a provider of market data for the auto industry.</p>\n<p><b>EARLY MISSTEP</b></p>\n<p>Some of Ford's missteps can be traced to when it drove into India in the mid-1990s alongside Hyundai. Whereas Hyundai entered with the small, affordable \"Santro\", Ford offered the \"Escort\" saloon, first launched in Europe in the 1960s.</p>\n<p>The Escort's price shocked Indians used to Maruti Suzuki's more affordable prices, said former Ford India executive Vinay Piparsania.</p>\n<p>Ford's narrow product range also made it hard to capitalise on the appeal won by its best-selling EcoSport and Endeavour sport utility vehicles (SUVs), said analyst Ammar Master at LMC.</p>\n<p>The carmaker said it had considered bringing more models to India but determined it could not do so profitably.</p>\n<p>\"The struggle for many global brands has always been meeting India's price point because they brought global products that were developed for mature markets at a high-cost structure,\" said Master.</p>\n<p>A peculiarity of the Indian market came in mid-2000 with a lower tax rate for cars measuring less than 4 metres (13.12 ft) in length. That left Ford and rivals building India-specific sub-4 metre saloons for which sales ultimately disappointed.</p>\n<p>\"U.S. manufacturers with large truck DNAs struggled to create a good and profitable small vehicle. Nobody got the product quite right and losses piled up,\" said JATO's Bhatia.</p>\n<p><b>RISE AND FALL</b></p>\n<p>Ford had excess capacity at its first India plant when it invested $1 billion on a second in 2015. It had planned to make India an export base and raise its share of a market projected to hit 7 million cars a year by 2020 and 9 million by 2025.</p>\n<p>But the sales never followed and overall market growth stalled. Ford now utilises only about 20% of its combined annual capacity of 440,000 cars.</p>\n<p>To use its excess capacity, Ford planned to build compact cars in India for emerging markets but shelved plans</p>\n<p>in 2016 amid a global consumer preference shift to SUVs.</p>\n<p>It changed its cost structure in 2018 and the following year started work on a joint venture with local peer Mahindra &amp; Mahindra Ltd</p>\n<p>designed to reduce costs. Three years later, in December, the partners abandoned the idea</p>\n<p>After sinking $2.5 billion in India since entry and burning another $2 billion over the past decade alone, Ford decided not to invest more.</p>\n<p>\"To continue investing ... we needed to show a path for a reasonable return on investment,\" Ford India head Anurag Mehrotra told reporters last week.</p>\n<p>\"Unfortunately, we are not able to do that.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168264185","content_text":"NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s, U.S. carmakers believed they were buying into a boom - the next China.\nThe economy had been liberalised in 1991, the government was welcoming investors, and the middle class was expected to fuel a consumption frenzy. Rising disposable income would help foreign carmakers to a market share of as much as 10%, forecasters said.\nIt never happened.\nLast week, Ford took a $2 billion hit to stop making cars in India, following compatriots General Motors Co and Harley-Davidson Inc in closing factories in the country.\nAmong foreigners that remain, Japan's Nissan Motor Co Ltd and even Germany's Volkswagen AG - the world's biggest automaker by sales - each hold less than 1% of a car market once forecast to be the third-largest by 2020, after China and the United States, with annual sales of 5 million.\nInstead, sales have stagnated at about 3 million cars. The growth rate has slowed to 3.6% in the last decade versus 12% a decade earlier.\nFord's retreat marks the end of an Indian dream for U.S. carmakers. It also follows its exit from Brazil announced in January reflecting an industry pivot from emerging markets to what is now widely seen as make-or-break investment in electric vehicles.\nAnalysts and executives said foreigners badly misjudged India's potential and underestimated the complexities of operating in a vast country that rewards domestic procurement.\nMany failed to adapt to a preference for small, cheap, fuel-efficient cars that could bump over uneven roads without needing expensive repairs. In India, 95% of cars are priced below $20,000.\nLower tax on small cars also made it harder for makers of larger cars for Western markets to compete with small-car specialists such as Japan's Suzuki Motor Corp - controlling shareholder of Maruti Suzuki India Ltd , India's biggest carmaker by sales.\nOf foreign carmakers that invested alone in India over the past 25 years, analysts said only South Korea's Hyundai Motor Co\nstands out as a success, mainly due to its wide portfolio of small cars and a grasp of what Indian buyers want.\n\"Companies invested on the fallacy that India would have great potential and the purchasing power of buyers would go up, but the government failed to create that kind of environment and infrastructure,\" said Ravi Bhatia, president for India at JATO Dynamics, a provider of market data for the auto industry.\nEARLY MISSTEP\nSome of Ford's missteps can be traced to when it drove into India in the mid-1990s alongside Hyundai. Whereas Hyundai entered with the small, affordable \"Santro\", Ford offered the \"Escort\" saloon, first launched in Europe in the 1960s.\nThe Escort's price shocked Indians used to Maruti Suzuki's more affordable prices, said former Ford India executive Vinay Piparsania.\nFord's narrow product range also made it hard to capitalise on the appeal won by its best-selling EcoSport and Endeavour sport utility vehicles (SUVs), said analyst Ammar Master at LMC.\nThe carmaker said it had considered bringing more models to India but determined it could not do so profitably.\n\"The struggle for many global brands has always been meeting India's price point because they brought global products that were developed for mature markets at a high-cost structure,\" said Master.\nA peculiarity of the Indian market came in mid-2000 with a lower tax rate for cars measuring less than 4 metres (13.12 ft) in length. That left Ford and rivals building India-specific sub-4 metre saloons for which sales ultimately disappointed.\n\"U.S. manufacturers with large truck DNAs struggled to create a good and profitable small vehicle. Nobody got the product quite right and losses piled up,\" said JATO's Bhatia.\nRISE AND FALL\nFord had excess capacity at its first India plant when it invested $1 billion on a second in 2015. It had planned to make India an export base and raise its share of a market projected to hit 7 million cars a year by 2020 and 9 million by 2025.\nBut the sales never followed and overall market growth stalled. Ford now utilises only about 20% of its combined annual capacity of 440,000 cars.\nTo use its excess capacity, Ford planned to build compact cars in India for emerging markets but shelved plans\nin 2016 amid a global consumer preference shift to SUVs.\nIt changed its cost structure in 2018 and the following year started work on a joint venture with local peer Mahindra & Mahindra Ltd\ndesigned to reduce costs. Three years later, in December, the partners abandoned the idea\nAfter sinking $2.5 billion in India since entry and burning another $2 billion over the past decade alone, Ford decided not to invest more.\n\"To continue investing ... we needed to show a path for a reasonable return on investment,\" Ford India head Anurag Mehrotra told reporters last week.\n\"Unfortunately, we are not able to do that.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885587411,"gmtCreate":1631803637033,"gmtModify":1676530640895,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CEI\">$Camber Energy(CEI)$</a>left pocket to right pocket... Just watching the show.","listText":"<a href=\"https://laohu8.com/S/CEI\">$Camber Energy(CEI)$</a>left pocket to right pocket... Just watching the show.","text":"$Camber Energy(CEI)$left pocket to right pocket... Just watching the show.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885587411","isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882591370,"gmtCreate":1631703883590,"gmtModify":1676530613091,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882591370","repostId":"1133293397","repostType":4,"repost":{"id":"1133293397","pubTimestamp":1631691783,"share":"https://ttm.financial/m/news/1133293397?lang=&edition=fundamental","pubTime":"2021-09-15 15:43","market":"us","language":"en","title":"Wall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.","url":"https://stock-news.laohu8.com/highlight/detail?id=1133293397","media":"Barrons","summary":"The stock market hasn’t had a formal correction all year and many strategists are now calling for on","content":"<p>The stock market hasn’t had a formal correction all year and many strategists are now calling for one. One bank still sees gains ahead because companies’ earnings are too good to ignore, but the rally it has penciled in would be far from spectacular.</p>\n<p>Several strategists are now looking for a negative return on the S&amp;P 500 by the end of the year. Some are calling for a correction, defined as a drawdown of at least 10%. The largest decline in the market benchmark so far this year was just 5%.</p>\n<p>Several factors, including valuations, could trigger the drop. The average stock on the&nbsp;S&amp;P 500&nbsp;currently trades at just under 21 times the earnings per share expected for the next 12 months. That is more than 35% higher than the long-term average.</p>\n<p>Falling bond yields, which make future profits worth more in current terms, have lifted valuations. But with the yield on 10-year Treasury debt currently at 1.31%— well below long-term inflation expectations of above 2%, a rare occurrence in the bond market—the decline could easily be over.Morgan Stanley‘s chief U.S. equity strategist, Mike Wilson, sees the 10-year yield hitting 1.8% by year-end, and the S&amp;P 500’s earnings multiple falling to 19 times.</p>\n<p>Even assuming corporate earnings are unaffected, this would mean severe downside for stocks. Wilson’s call on the level of the S&amp;P 500 relative to the aggregate per-share earnings of the companies included would bring the index down 9%.</p>\n<p>Stifel’s head of institutional equity strategy, Barry Bannister, said in a recent research note that lower earnings multiples resulting from higher bond yields could mean the S&amp;P 500 could fall 10% to 15%.</p>\n<p>Profits are another potential trouble spot, not least because of supply-chain issues. Already, several companies have lowered their forecasts for sales and earnings for the current quarter because problems getting parts are lowering their customers’—and their own—production. Analysts and management teams expect strong demand to lift profits when the supply problems ease and inventory levels climb again, but it isn’t clear when that might happen, or how bad the shortages of parts and finished goods could become.</p>\n<p>“This [supply constraints] will be a more substantial risk to the rally we’ll need to watch for,” wrote Tom Essaye, founder of Sevens Report Research. Prolonged trouble could mean unexpectedly severe damage to profits.</p>\n<p>Higher corporate taxes would also bring earnings down, but stock prices don’t seem to be reflecting that risk.Goldman Sachs&nbsp;strategists said earlier this year that S&amp;P 500 EPS could fall 5% if the corporate tax rate rises to 25% from 21% — and House Democrats proposed an increase to 26.5% on Monday.</p>\n<p>Still, RBC strategists raised their S&amp;P 500 price target to 4,500 on Monday. They now see S&amp;P 500 earnings per share for 2022 coming in at $222, only slightly above the consensus call of $218 among analysts. While RBC acknowledges the average multiple may fall to just above 20 times, its call implies a gain of just 0.7% relative to Monday’s closing level.</p>\n<p>Even the more bullish observers aren’t forecasting anything exciting for stocks.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 15:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/s-p-500-correction-outlook-strategists-51631632149?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market hasn’t had a formal correction all year and many strategists are now calling for one. One bank still sees gains ahead because companies’ earnings are too good to ignore, but the rally...</p>\n\n<a href=\"https://www.barrons.com/articles/s-p-500-correction-outlook-strategists-51631632149?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.barrons.com/articles/s-p-500-correction-outlook-strategists-51631632149?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133293397","content_text":"The stock market hasn’t had a formal correction all year and many strategists are now calling for one. One bank still sees gains ahead because companies’ earnings are too good to ignore, but the rally it has penciled in would be far from spectacular.\nSeveral strategists are now looking for a negative return on the S&P 500 by the end of the year. Some are calling for a correction, defined as a drawdown of at least 10%. The largest decline in the market benchmark so far this year was just 5%.\nSeveral factors, including valuations, could trigger the drop. The average stock on the S&P 500 currently trades at just under 21 times the earnings per share expected for the next 12 months. That is more than 35% higher than the long-term average.\nFalling bond yields, which make future profits worth more in current terms, have lifted valuations. But with the yield on 10-year Treasury debt currently at 1.31%— well below long-term inflation expectations of above 2%, a rare occurrence in the bond market—the decline could easily be over.Morgan Stanley‘s chief U.S. equity strategist, Mike Wilson, sees the 10-year yield hitting 1.8% by year-end, and the S&P 500’s earnings multiple falling to 19 times.\nEven assuming corporate earnings are unaffected, this would mean severe downside for stocks. Wilson’s call on the level of the S&P 500 relative to the aggregate per-share earnings of the companies included would bring the index down 9%.\nStifel’s head of institutional equity strategy, Barry Bannister, said in a recent research note that lower earnings multiples resulting from higher bond yields could mean the S&P 500 could fall 10% to 15%.\nProfits are another potential trouble spot, not least because of supply-chain issues. Already, several companies have lowered their forecasts for sales and earnings for the current quarter because problems getting parts are lowering their customers’—and their own—production. Analysts and management teams expect strong demand to lift profits when the supply problems ease and inventory levels climb again, but it isn’t clear when that might happen, or how bad the shortages of parts and finished goods could become.\n“This [supply constraints] will be a more substantial risk to the rally we’ll need to watch for,” wrote Tom Essaye, founder of Sevens Report Research. Prolonged trouble could mean unexpectedly severe damage to profits.\nHigher corporate taxes would also bring earnings down, but stock prices don’t seem to be reflecting that risk.Goldman Sachs strategists said earlier this year that S&P 500 EPS could fall 5% if the corporate tax rate rises to 25% from 21% — and House Democrats proposed an increase to 26.5% on Monday.\nStill, RBC strategists raised their S&P 500 price target to 4,500 on Monday. They now see S&P 500 earnings per share for 2022 coming in at $222, only slightly above the consensus call of $218 among analysts. While RBC acknowledges the average multiple may fall to just above 20 times, its call implies a gain of just 0.7% relative to Monday’s closing level.\nEven the more bullish observers aren’t forecasting anything exciting for stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886588272,"gmtCreate":1631605657996,"gmtModify":1676530587936,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886588272","repostId":"2167044533","repostType":2,"repost":{"id":"2167044533","pubTimestamp":1631575849,"share":"https://ttm.financial/m/news/2167044533?lang=&edition=fundamental","pubTime":"2021-09-14 07:30","market":"us","language":"en","title":"Why SmileDirectClub Shares Surged Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2167044533","media":"Benzinga","summary":"SmileDirectClub Inc (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's sessio","content":"<p><b>SmileDirectClub Inc</b> (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's session as&nbsp;traders on social media circulate the stock, highlighting its high short interest.</p>\n<p>The average session&nbsp;volume is about 6.5 million. The daily trading&nbsp;volume for Monday's session was over 42 million.</p>\n<p>SmileDirectClub was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top three trending stocks on Stocktwits at publication time.</p>\n<p>The percentage of the float sold short is about 33%, according to data from&nbsp;Benzinga Pro.</p>\n<p>SmileDirectClub&nbsp;is engaged in the orthodontics business. It is mainly involved in the sale of aligners, impression kits, whitening gel&nbsp;and retainers.</p>\n<p><b>SDC Price Action:</b> SmileDirectClub has traded as high as $16.07 and as low as $4.63 over a 52-week period.</p>\n<p>The stock closed up 16.12% at $5.98 on Monday.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why SmileDirectClub Shares Surged Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy SmileDirectClub Shares Surged Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-14 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-smiledirectclub-shares-surged-higher-201349699.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SmileDirectClub Inc (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's session as traders on social media circulate the stock, highlighting its high short interest.\nThe average ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-smiledirectclub-shares-surged-higher-201349699.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SDC":"SmileDirectClub, Inc."},"source_url":"https://finance.yahoo.com/news/why-smiledirectclub-shares-surged-higher-201349699.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167044533","content_text":"SmileDirectClub Inc (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's session as traders on social media circulate the stock, highlighting its high short interest.\nThe average session volume is about 6.5 million. The daily trading volume for Monday's session was over 42 million.\nSmileDirectClub was one of the top three trending stocks on Stocktwits at publication time.\nThe percentage of the float sold short is about 33%, according to data from Benzinga Pro.\nSmileDirectClub is engaged in the orthodontics business. It is mainly involved in the sale of aligners, impression kits, whitening gel and retainers.\nSDC Price Action: SmileDirectClub has traded as high as $16.07 and as low as $4.63 over a 52-week period.\nThe stock closed up 16.12% at $5.98 on Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":466,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881884341,"gmtCreate":1631324001183,"gmtModify":1676530528288,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Let's see Oct 1.","listText":"Let's see Oct 1.","text":"Let's see Oct 1.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881884341","repostId":"1117774965","repostType":2,"repost":{"id":"1117774965","pubTimestamp":1630336580,"share":"https://ttm.financial/m/news/1117774965?lang=&edition=fundamental","pubTime":"2021-08-30 23:16","market":"us","language":"en","title":"BBIG Stock: 10 Things to Know About Reddit Favorite and Short-Squeeze Target Vinco Ventures","url":"https://stock-news.laohu8.com/highlight/detail?id=1117774965","media":"investorplace","summary":"Vinco Ventures(NASDAQ:BBIG) stock is running higher on Monday as Reddit and retail traders on social","content":"<p><b>Vinco Ventures</b>(NASDAQ:<b><u>BBIG</u></b>) stock is running higher on Monday as Reddit and retail traders on social media pump shares up.</p>\n<p>We’ve been covering BBIG stock quite a bit lately as it continues to be a hot stock with major movement. That includes it ranking high in ourlist of pre-market stock movers for this morning. We also dived into&nbsp;what experts had to say about it last week.</p>\n<p>Now we’re tackling it again with some details that traders will want to know about BBIG stock.</p>\n<ul>\n <li>Vinco Ventures is a company&nbsp;focused on acquiring and growing companies.</li>\n <li>It does so through its B.I.G. Strategy: Buy. Innovate. Grow.</li>\n <li>One of the most recent shifts in its business has it targeting the non-fungible token (NFT) market.</li>\n <li>Emmersive Entertainment, a subsidiary of Vinco Ventures, is already making progress in the NFT space.</li>\n <li>That includes the launch of a music streaming NFT platform and a promotion with Tory Lanez.</li>\n <li>However, there are still concerns about the company’s business.</li>\n <li>That includes issues that some people have with NFTs and their connection to crypto.</li>\n <li>There are also&nbsp;worries about Ted Farnsworth’s involvement&nbsp;in Vinco Ventures’ NFT business.</li>\n <li>Farnsworth is the creator of MoviePass, which blew up in spectacular fashion a few years back.</li>\n <li>While the potential of BBIG in the NFT space is there, investors will want to keep the above in mind before diving into the stock.</li>\n</ul>\n<p>Of course, BBIG is also seeing heavy trading today with the interest from meme stock traders. As of this writing, more than 178 million shares of the stock have changed hands. That’s a massive jump from the company’s daily average trading volume of 18.4 million shares.</p>\n<p>BBIG stock was up 50% as of Monday morning.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BBIG Stock: 10 Things to Know About Reddit Favorite and Short-Squeeze Target Vinco Ventures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBBIG Stock: 10 Things to Know About Reddit Favorite and Short-Squeeze Target Vinco Ventures\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/bbig-stock-10-things-to-know-about-reddit-favorite-and-short-squeeze-target-vinco-ventures/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vinco Ventures(NASDAQ:BBIG) stock is running higher on Monday as Reddit and retail traders on social media pump shares up.\nWe’ve been covering BBIG stock quite a bit lately as it continues to be a hot...</p>\n\n<a href=\"https://investorplace.com/2021/08/bbig-stock-10-things-to-know-about-reddit-favorite-and-short-squeeze-target-vinco-ventures/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BBIG":"Vinco Ventures, Inc."},"source_url":"https://investorplace.com/2021/08/bbig-stock-10-things-to-know-about-reddit-favorite-and-short-squeeze-target-vinco-ventures/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117774965","content_text":"Vinco Ventures(NASDAQ:BBIG) stock is running higher on Monday as Reddit and retail traders on social media pump shares up.\nWe’ve been covering BBIG stock quite a bit lately as it continues to be a hot stock with major movement. That includes it ranking high in ourlist of pre-market stock movers for this morning. We also dived into what experts had to say about it last week.\nNow we’re tackling it again with some details that traders will want to know about BBIG stock.\n\nVinco Ventures is a company focused on acquiring and growing companies.\nIt does so through its B.I.G. Strategy: Buy. Innovate. Grow.\nOne of the most recent shifts in its business has it targeting the non-fungible token (NFT) market.\nEmmersive Entertainment, a subsidiary of Vinco Ventures, is already making progress in the NFT space.\nThat includes the launch of a music streaming NFT platform and a promotion with Tory Lanez.\nHowever, there are still concerns about the company’s business.\nThat includes issues that some people have with NFTs and their connection to crypto.\nThere are also worries about Ted Farnsworth’s involvement in Vinco Ventures’ NFT business.\nFarnsworth is the creator of MoviePass, which blew up in spectacular fashion a few years back.\nWhile the potential of BBIG in the NFT space is there, investors will want to keep the above in mind before diving into the stock.\n\nOf course, BBIG is also seeing heavy trading today with the interest from meme stock traders. As of this writing, more than 178 million shares of the stock have changed hands. That’s a massive jump from the company’s daily average trading volume of 18.4 million shares.\nBBIG stock was up 50% as of Monday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883817099,"gmtCreate":1631232486611,"gmtModify":1676530501779,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Means good time to buy now before skyrocketing next year, ok I'll buy. Investment in dip not when is exploded.","listText":"Means good time to buy now before skyrocketing next year, ok I'll buy. Investment in dip not when is exploded.","text":"Means good time to buy now before skyrocketing next year, ok I'll buy. Investment in dip not when is exploded.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883817099","repostId":"1147371212","repostType":2,"repost":{"id":"1147371212","pubTimestamp":1630399960,"share":"https://ttm.financial/m/news/1147371212?lang=&edition=fundamental","pubTime":"2021-08-31 16:52","market":"us","language":"en","title":"Apple's satellite iPhone features to focus on emergencies only","url":"https://stock-news.laohu8.com/highlight/detail?id=1147371212","media":"seekingalpha","summary":"Apple's(NASDAQ:AAPL)reported push to add satellite capabilities to the iPhone will be focused on eme","content":"<ul>\n <li>Apple's(NASDAQ:AAPL)reported push to&nbsp;add satellite capabilities to the iPhone&nbsp;will be focused on emergencies, Bloomberg reports - such as&nbsp;allowing users to issue crash reports in areas without cellular coverage or text first responders.</li>\n <li>And those features aren't due soon, but rather for future iPhones, according to the report.</li>\n <li>Speculation based on an earlier MacRumors report led observers to believe satellite capability might be in the upcoming iPhone 13.</li>\n <li>But Apple's approach is set to be more limited at first, according to Bloomberg, and not arrive until at least next year.</li>\n <li>Stocks in satellite connectivity providers jumped earlier today, before mobile analysts rushed in to suggest that the upcoming phone wouldn't necessarily have satellite capabilities such that it could stop relying on cell networks.</li>\n <li>Globalstar(NYSE:GSAT)finished the day&nbsp;up 64.3%and its shares are now&nbsp;down 8.9%after hours. Iridium Communications(NASDAQ:IRDM),up 15.4%on the regular session, is&nbsp;down 5%postmarket. And AST SpaceMobile(NASDAQ:ASTS),up 12.5%on the day, is&nbsp;off 1.7%after hours.</li>\n <li>But those new Apple features sound like they would compete with Garmin's inReach device. Garmin(NASDAQ:GRMN)rose 1.4%today and is&nbsp;up 0.4%after hours.</li>\n <li>It was a&nbsp;busy day elsewhere for Apple, which closed at an all-time high after news including IDC expectations for a 14% rise in iPhone shipments and developments on the entertainment front.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple's satellite iPhone features to focus on emergencies only</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple's satellite iPhone features to focus on emergencies only\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 16:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3735446-apples-satellite-iphone-features-to-focus-on-emergencies-only-bloomberg><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple's(NASDAQ:AAPL)reported push to add satellite capabilities to the iPhone will be focused on emergencies, Bloomberg reports - such as allowing users to issue crash reports in areas without ...</p>\n\n<a href=\"https://seekingalpha.com/news/3735446-apples-satellite-iphone-features-to-focus-on-emergencies-only-bloomberg\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSAT":"全球星","AAPL":"苹果"},"source_url":"https://seekingalpha.com/news/3735446-apples-satellite-iphone-features-to-focus-on-emergencies-only-bloomberg","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1147371212","content_text":"Apple's(NASDAQ:AAPL)reported push to add satellite capabilities to the iPhone will be focused on emergencies, Bloomberg reports - such as allowing users to issue crash reports in areas without cellular coverage or text first responders.\nAnd those features aren't due soon, but rather for future iPhones, according to the report.\nSpeculation based on an earlier MacRumors report led observers to believe satellite capability might be in the upcoming iPhone 13.\nBut Apple's approach is set to be more limited at first, according to Bloomberg, and not arrive until at least next year.\nStocks in satellite connectivity providers jumped earlier today, before mobile analysts rushed in to suggest that the upcoming phone wouldn't necessarily have satellite capabilities such that it could stop relying on cell networks.\nGlobalstar(NYSE:GSAT)finished the day up 64.3%and its shares are now down 8.9%after hours. Iridium Communications(NASDAQ:IRDM),up 15.4%on the regular session, is down 5%postmarket. And AST SpaceMobile(NASDAQ:ASTS),up 12.5%on the day, is off 1.7%after hours.\nBut those new Apple features sound like they would compete with Garmin's inReach device. Garmin(NASDAQ:GRMN)rose 1.4%today and is up 0.4%after hours.\nIt was a busy day elsewhere for Apple, which closed at an all-time high after news including IDC expectations for a 14% rise in iPhone shipments and developments on the entertainment front.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889525580,"gmtCreate":1631160677840,"gmtModify":1676530483898,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889525580","repostId":"2165393291","repostType":2,"repost":{"id":"2165393291","weMediaInfo":{"introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"media_name":"GlobeNewswire","id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"pubTimestamp":1631073600,"share":"https://ttm.financial/m/news/2165393291?lang=&edition=fundamental","pubTime":"2021-09-08 12:00","market":"hk","language":"en","title":"Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins","url":"https://stock-news.laohu8.com/highlight/detail?id=2165393291","media":"GlobeNewswire","summary":"FoxP3+ Regulatory T-Cells\n\n\n\n\nC57BL/6 mice (n=7/group) were untreated or were treated with ImmTOR al","content":"<html><body><div>\n<div>\n<h4>FoxP3+ Regulatory T-Cells</h4>\n<div>\n<img src=\"https://ml.globenewswire.com/Resource/Download/eb50b792-d824-4b4b-8e60-c2135fe26e2e?size=2\"/>\n</div>\n<div>\n<h5>C57BL/6 mice (n=7/group) were untreated or were treated with ImmTOR alone, IL-2 mutein alone, or a combination of ImmTOR + IL-2 mutein.  The mouse-specific IL-2 mutein was produced as described by Khoryati et al. (Sci. Immunol. , 2020, 5, eaba5264). Expansion of CD4+, CD25+, FoxP3+ T regulatory cells in the spleen was assessed 7 days after treatment.  ***p&lt;0.001, Mann-Whitney test.</h5>\n</div>\n</div>\n</div><p><em>- First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions-</em><br/></p> <p><em>-Preclinical data demonstrate synergistic activity of ImmTOR in combination with IL-2 mutein to increase the level and durability of T</em><sub><em>reg</em></sub><em> expansion-</em></p> <p><em>- Unlocking a new generation of innovative biologic therapeutics with the potential to improve the lives of patients-</em></p> <p>WATERTOWN, Mass. and SEATTLE, Sept.  08, 2021  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Cyrus Biotechnology, Inc. a leading protein design company, today announced a protein engineering collaboration combining Selecta’s ImmTOR platform with Cyrus’ ability to radically redesign protein therapeutics. The lead program in the collaboration is a proprietary interleukin-2 (IL-2) protein agonist designed to selectively promote expansion of regulatory T cells (T<sub>reg</sub>) for the treatment of patients with autoimmune diseases and other deleterious immune conditions.</p> <p>Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells (T<sub>reg</sub>). These T<sub>reg</sub> cells are a specialized subpopulation of T cells involved in suppressing certain immune responses and maintaining the body’s self-tolerance. Reductions in the number of T<sub>reg</sub> cells have been shown to drive a spectrum of autoimmune diseases and conversely, increasing T<sub>reg</sub> expansion may have clinical utility in reducing inflammation and improving disease outcomes. Early preclinical data investigating the effects of ImmTOR in combination with a T<sub>reg</sub>-selective IL-2 mutant protein (IL-2 “mutein”) demonstrate substantial synergistic activity in increasing the percentage and durability of T<sub>reg</sub> expansion in the spleen (Figure below). This supports the potential of ImmTOR in combination with IL-2 proteins to restore immunotolerance to autoantigens and forms the basis for this partnership. Although IL-2 has been an attractive target for autoimmune indications, overcoming its immunostimulatory activities, short half-life and anti-IL-2 antibody formation has been challenging. Building on recent advancements in the field, our strong preliminary data suggest that ImmTOR in combination with Cyrus’ novel IL-2 protein agonist has the potential to unlock the value of this target and drive the development of a next generation, best-in-class asset.</p> <p>A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb50b792-d824-4b4b-8e60-c2135fe26e2e</p> <p>“We are excited to collaborate with Cyrus, and we see this strategic protein engineering partnership as an important step in advancing our ImmTOR platform for the treatment of autoimmune diseases,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. “We are encouraged by the preclinical data generated to date and the growing literature that supports the potential of IL-2 therapeutics in treating immunological diseases.”</p> <p>Dr. Brunn added, “We look forward to leveraging Cyrus’ ability to both reengineer immune epitopes and rationally design novel proteins using non-traditional starting sequences, including non-human, non-natural and ancestral versions. For our first program, this combination will allow us to potentially mitigate unwanted immune responses by reducing the inherent immunogenicity of the protein while also promoting immune tolerance. We are fortunate to have this opportunity to optimize and advance our portfolio through the design and generation of innovative protein therapeutics. Beyond leading a paradigm shift in the way biologics are made, ultimately this collaboration has the potential to unlock new treatment options and improve the lives of patients who suffer from serious and debilitating diseases.”</p> <p>Lucas Nivon, Ph.D., Chief Executive Officer of Cyrus, commented, “We welcome Selecta as a deeply experienced partner. This collaboration is in perfect alignment with our protein design expertise and represents an important endorsement of our platform, which has the potential to further enhance the potency of ImmTOR’s tolerizing power. With our current partners, we have demonstrated our ability to redesign existing protein biologics or build them from the ground-up -- expanding the potential for therapeutics and intellectual property. We look forward to executing on our shared vision.”</p> <p>Under the terms of the collaboration, Selecta has provided an upfront payment, and Cyrus is eligible to earn discovery, development and sales based milestones. Novel engineered protein therapeutic candidates from the partnership will be used to expand Selecta’s proprietary pipeline and further bolster Selecta’s clinically validated ImmTOR platform.</p> <p><strong>About Selecta Biosciences, Inc.</strong><br/><a href=\"https://laohu8.com/S/SELB\">Selecta Biosciences Inc</a>. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.</p> <p><strong>About Cyrus Biotechnology</strong><br/>Cyrus Biotechnology is a pre-clinical-stage biotechnology company applying leading computational protein design capabilities coupled with massively parallel <em>in vitro</em> screening to engineer novel biologics drugs. Cyrus is advancing a novel pre-clinical infectious disease therapeutic and developing a pipeline of internal and partnered discovery programs over a range of indications, including next-generation CRISPR therapeutics in collaboration with the Broad Institute. Cyrus founders include Dr. David Baker of the University of Washington and the company’s platform is based on core software from the Baker lab. The company has worked with over 100 industry partners, including 13 of the top 20 global Pharma firms. Cyrus is based in Seattle, WA and financed by leading Biotech and Tech investors including Orbimed, Trinity, Springrock, WRF and Alexandria. For more information please visit cyrusbio.com.</p> <p><strong>Selecta Forward-Looking Statements</strong><br/><em>Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the Company”), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the programs and disease indication targets anticipated under this collaboration, the potential of our partners to develop or redesign any protein therapeutics, the ability of any drug candidate developed under the collaboration to offer a therapeutic benefit, including the promotion of expansion of regulatory T cells for the treatment of autoimmune disease indications, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company’s product pipeline to treat chronic refractory gout, IgA nephropathy, PBC, MMA or OTC, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the Company’s ability to conduct those clinical trials and studies, the timing or making of any regulatory filings, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human primate study subjects will translate to studies performed with human beings, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company’s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the Company’s intellectual property to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the Company’s ability to grow its strategic partnerships, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human primates, the unproven approach of the Company’s ImmTOR technology, our partners’ ability to re-engineer or develop any protein therapeutics, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q to be filed after this release, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release.</em></p> <p><strong>For Investors:</strong><br/>Bruce Mackle<br/>LifeSci Advisors, LLC<br/>+1-929-469-3859<br/>bmackle@lifesciadvisors.com</p> <p><strong>For Media: </strong><br/>Brittany Leigh, Ph.D.<br/>LifeSci Communications, LLC<br/>+1-646-751-4366<br/>bleigh@lifescicomms.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NWZhMWQzNmMtYTc2Ni00YjdmLWI5NGMtM2I2YzdhZjY0MDg5LTUwMDA3NjYxMA==/tiny/Selecta-Biosciences-Inc-.png\"/></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSelecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2021-09-08 12:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<h4>FoxP3+ Regulatory T-Cells</h4>\n<div>\n<img src=\"https://ml.globenewswire.com/Resource/Download/eb50b792-d824-4b4b-8e60-c2135fe26e2e?size=2\"/>\n</div>\n<div>\n<h5>C57BL/6 mice (n=7/group) were untreated or were treated with ImmTOR alone, IL-2 mutein alone, or a combination of ImmTOR + IL-2 mutein.  The mouse-specific IL-2 mutein was produced as described by Khoryati et al. (Sci. Immunol. , 2020, 5, eaba5264). Expansion of CD4+, CD25+, FoxP3+ T regulatory cells in the spleen was assessed 7 days after treatment.  ***p&lt;0.001, Mann-Whitney test.</h5>\n</div>\n</div>\n</div><p><em>- First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions-</em><br/></p> <p><em>-Preclinical data demonstrate synergistic activity of ImmTOR in combination with IL-2 mutein to increase the level and durability of T</em><sub><em>reg</em></sub><em> expansion-</em></p> <p><em>- Unlocking a new generation of innovative biologic therapeutics with the potential to improve the lives of patients-</em></p> <p>WATERTOWN, Mass. and SEATTLE, Sept.  08, 2021  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Cyrus Biotechnology, Inc. a leading protein design company, today announced a protein engineering collaboration combining Selecta’s ImmTOR platform with Cyrus’ ability to radically redesign protein therapeutics. The lead program in the collaboration is a proprietary interleukin-2 (IL-2) protein agonist designed to selectively promote expansion of regulatory T cells (T<sub>reg</sub>) for the treatment of patients with autoimmune diseases and other deleterious immune conditions.</p> <p>Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells (T<sub>reg</sub>). These T<sub>reg</sub> cells are a specialized subpopulation of T cells involved in suppressing certain immune responses and maintaining the body’s self-tolerance. Reductions in the number of T<sub>reg</sub> cells have been shown to drive a spectrum of autoimmune diseases and conversely, increasing T<sub>reg</sub> expansion may have clinical utility in reducing inflammation and improving disease outcomes. Early preclinical data investigating the effects of ImmTOR in combination with a T<sub>reg</sub>-selective IL-2 mutant protein (IL-2 “mutein”) demonstrate substantial synergistic activity in increasing the percentage and durability of T<sub>reg</sub> expansion in the spleen (Figure below). This supports the potential of ImmTOR in combination with IL-2 proteins to restore immunotolerance to autoantigens and forms the basis for this partnership. Although IL-2 has been an attractive target for autoimmune indications, overcoming its immunostimulatory activities, short half-life and anti-IL-2 antibody formation has been challenging. Building on recent advancements in the field, our strong preliminary data suggest that ImmTOR in combination with Cyrus’ novel IL-2 protein agonist has the potential to unlock the value of this target and drive the development of a next generation, best-in-class asset.</p> <p>A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb50b792-d824-4b4b-8e60-c2135fe26e2e</p> <p>“We are excited to collaborate with Cyrus, and we see this strategic protein engineering partnership as an important step in advancing our ImmTOR platform for the treatment of autoimmune diseases,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. “We are encouraged by the preclinical data generated to date and the growing literature that supports the potential of IL-2 therapeutics in treating immunological diseases.”</p> <p>Dr. Brunn added, “We look forward to leveraging Cyrus’ ability to both reengineer immune epitopes and rationally design novel proteins using non-traditional starting sequences, including non-human, non-natural and ancestral versions. For our first program, this combination will allow us to potentially mitigate unwanted immune responses by reducing the inherent immunogenicity of the protein while also promoting immune tolerance. We are fortunate to have this opportunity to optimize and advance our portfolio through the design and generation of innovative protein therapeutics. Beyond leading a paradigm shift in the way biologics are made, ultimately this collaboration has the potential to unlock new treatment options and improve the lives of patients who suffer from serious and debilitating diseases.”</p> <p>Lucas Nivon, Ph.D., Chief Executive Officer of Cyrus, commented, “We welcome Selecta as a deeply experienced partner. This collaboration is in perfect alignment with our protein design expertise and represents an important endorsement of our platform, which has the potential to further enhance the potency of ImmTOR’s tolerizing power. With our current partners, we have demonstrated our ability to redesign existing protein biologics or build them from the ground-up -- expanding the potential for therapeutics and intellectual property. We look forward to executing on our shared vision.”</p> <p>Under the terms of the collaboration, Selecta has provided an upfront payment, and Cyrus is eligible to earn discovery, development and sales based milestones. Novel engineered protein therapeutic candidates from the partnership will be used to expand Selecta’s proprietary pipeline and further bolster Selecta’s clinically validated ImmTOR platform.</p> <p><strong>About Selecta Biosciences, Inc.</strong><br/><a href=\"https://laohu8.com/S/SELB\">Selecta Biosciences Inc</a>. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.</p> <p><strong>About Cyrus Biotechnology</strong><br/>Cyrus Biotechnology is a pre-clinical-stage biotechnology company applying leading computational protein design capabilities coupled with massively parallel <em>in vitro</em> screening to engineer novel biologics drugs. Cyrus is advancing a novel pre-clinical infectious disease therapeutic and developing a pipeline of internal and partnered discovery programs over a range of indications, including next-generation CRISPR therapeutics in collaboration with the Broad Institute. Cyrus founders include Dr. David Baker of the University of Washington and the company’s platform is based on core software from the Baker lab. The company has worked with over 100 industry partners, including 13 of the top 20 global Pharma firms. Cyrus is based in Seattle, WA and financed by leading Biotech and Tech investors including Orbimed, Trinity, Springrock, WRF and Alexandria. For more information please visit cyrusbio.com.</p> <p><strong>Selecta Forward-Looking Statements</strong><br/><em>Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the Company”), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the programs and disease indication targets anticipated under this collaboration, the potential of our partners to develop or redesign any protein therapeutics, the ability of any drug candidate developed under the collaboration to offer a therapeutic benefit, including the promotion of expansion of regulatory T cells for the treatment of autoimmune disease indications, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company’s product pipeline to treat chronic refractory gout, IgA nephropathy, PBC, MMA or OTC, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the Company’s ability to conduct those clinical trials and studies, the timing or making of any regulatory filings, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human primate study subjects will translate to studies performed with human beings, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company’s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the Company’s intellectual property to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the Company’s ability to grow its strategic partnerships, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human primates, the unproven approach of the Company’s ImmTOR technology, our partners’ ability to re-engineer or develop any protein therapeutics, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q to be filed after this release, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release.</em></p> <p><strong>For Investors:</strong><br/>Bruce Mackle<br/>LifeSci Advisors, LLC<br/>+1-929-469-3859<br/>bmackle@lifesciadvisors.com</p> <p><strong>For Media: </strong><br/>Brittany Leigh, Ph.D.<br/>LifeSci Communications, LLC<br/>+1-646-751-4366<br/>bleigh@lifescicomms.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NWZhMWQzNmMtYTc2Ni00YjdmLWI5NGMtM2I2YzdhZjY0MDg5LTUwMDA3NjYxMA==/tiny/Selecta-Biosciences-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.globenewswire.com/news-release/2021/09/08/2293345/0/en/Selecta-Biosciences-and-Cyrus-Biotechnology-Enter-Collaboration-to-Create-Novel-Engineered-Therapeutic-Proteins.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165393291","content_text":"FoxP3+ Regulatory T-Cells\n\n\n\n\nC57BL/6 mice (n=7/group) were untreated or were treated with ImmTOR alone, IL-2 mutein alone, or a combination of ImmTOR + IL-2 mutein.  The mouse-specific IL-2 mutein was produced as described by Khoryati et al. (Sci. Immunol. , 2020, 5, eaba5264). Expansion of CD4+, CD25+, FoxP3+ T regulatory cells in the spleen was assessed 7 days after treatment.  ***p<0.001, Mann-Whitney test.\n\n\n- First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical data demonstrate synergistic activity of ImmTOR in combination with IL-2 mutein to increase the level and durability of Treg expansion- - Unlocking a new generation of innovative biologic therapeutics with the potential to improve the lives of patients- WATERTOWN, Mass. and SEATTLE, Sept.  08, 2021  (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Cyrus Biotechnology, Inc. a leading protein design company, today announced a protein engineering collaboration combining Selecta’s ImmTOR platform with Cyrus’ ability to radically redesign protein therapeutics. The lead program in the collaboration is a proprietary interleukin-2 (IL-2) protein agonist designed to selectively promote expansion of regulatory T cells (Treg) for the treatment of patients with autoimmune diseases and other deleterious immune conditions. Novel IL-2 approaches and technologies are driving innovation in the therapeutic development space. The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells (Treg). These Treg cells are a specialized subpopulation of T cells involved in suppressing certain immune responses and maintaining the body’s self-tolerance. Reductions in the number of Treg cells have been shown to drive a spectrum of autoimmune diseases and conversely, increasing Treg expansion may have clinical utility in reducing inflammation and improving disease outcomes. Early preclinical data investigating the effects of ImmTOR in combination with a Treg-selective IL-2 mutant protein (IL-2 “mutein”) demonstrate substantial synergistic activity in increasing the percentage and durability of Treg expansion in the spleen (Figure below). This supports the potential of ImmTOR in combination with IL-2 proteins to restore immunotolerance to autoantigens and forms the basis for this partnership. Although IL-2 has been an attractive target for autoimmune indications, overcoming its immunostimulatory activities, short half-life and anti-IL-2 antibody formation has been challenging. Building on recent advancements in the field, our strong preliminary data suggest that ImmTOR in combination with Cyrus’ novel IL-2 protein agonist has the potential to unlock the value of this target and drive the development of a next generation, best-in-class asset. A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb50b792-d824-4b4b-8e60-c2135fe26e2e “We are excited to collaborate with Cyrus, and we see this strategic protein engineering partnership as an important step in advancing our ImmTOR platform for the treatment of autoimmune diseases,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. “We are encouraged by the preclinical data generated to date and the growing literature that supports the potential of IL-2 therapeutics in treating immunological diseases.” Dr. Brunn added, “We look forward to leveraging Cyrus’ ability to both reengineer immune epitopes and rationally design novel proteins using non-traditional starting sequences, including non-human, non-natural and ancestral versions. For our first program, this combination will allow us to potentially mitigate unwanted immune responses by reducing the inherent immunogenicity of the protein while also promoting immune tolerance. We are fortunate to have this opportunity to optimize and advance our portfolio through the design and generation of innovative protein therapeutics. Beyond leading a paradigm shift in the way biologics are made, ultimately this collaboration has the potential to unlock new treatment options and improve the lives of patients who suffer from serious and debilitating diseases.” Lucas Nivon, Ph.D., Chief Executive Officer of Cyrus, commented, “We welcome Selecta as a deeply experienced partner. This collaboration is in perfect alignment with our protein design expertise and represents an important endorsement of our platform, which has the potential to further enhance the potency of ImmTOR’s tolerizing power. With our current partners, we have demonstrated our ability to redesign existing protein biologics or build them from the ground-up -- expanding the potential for therapeutics and intellectual property. We look forward to executing on our shared vision.” Under the terms of the collaboration, Selecta has provided an upfront payment, and Cyrus is eligible to earn discovery, development and sales based milestones. Novel engineered protein therapeutic candidates from the partnership will be used to expand Selecta’s proprietary pipeline and further bolster Selecta’s clinically validated ImmTOR platform. About Selecta Biosciences, Inc.Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com. About Cyrus BiotechnologyCyrus Biotechnology is a pre-clinical-stage biotechnology company applying leading computational protein design capabilities coupled with massively parallel in vitro screening to engineer novel biologics drugs. Cyrus is advancing a novel pre-clinical infectious disease therapeutic and developing a pipeline of internal and partnered discovery programs over a range of indications, including next-generation CRISPR therapeutics in collaboration with the Broad Institute. Cyrus founders include Dr. David Baker of the University of Washington and the company’s platform is based on core software from the Baker lab. The company has worked with over 100 industry partners, including 13 of the top 20 global Pharma firms. Cyrus is based in Seattle, WA and financed by leading Biotech and Tech investors including Orbimed, Trinity, Springrock, WRF and Alexandria. For more information please visit cyrusbio.com. Selecta Forward-Looking StatementsAny statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the Company”), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the programs and disease indication targets anticipated under this collaboration, the potential of our partners to develop or redesign any protein therapeutics, the ability of any drug candidate developed under the collaboration to offer a therapeutic benefit, including the promotion of expansion of regulatory T cells for the treatment of autoimmune disease indications, the potential of ImmTOR to enable re-dosing of AAV gene therapy and to mitigate immunogenicity, the potential of ImmTOR and the Company’s product pipeline to treat chronic refractory gout, IgA nephropathy, PBC, MMA or OTC, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the Company’s ability to conduct those clinical trials and studies, the timing or making of any regulatory filings, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, gout and autoimmune disease, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, whether the observations made in non-human primate study subjects will translate to studies performed with human beings, the potential of any therapies developed by the Company to fulfill unmet medical needs, the Company’s plan to apply its ImmTOR technology platform to a range of biologics for rare and orphan genetic diseases, the potential of the Company’s intellectual property to enable repeat administration in gene therapy product candidates and products, the ability to re-dose patients and the potential of ImmTOR to allow for re-dosing, the potential to safely re-dose AAV, the ability to restore transgene expression, the potential of the ImmTOR technology platform generally and the Company’s ability to grow its strategic partnerships, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including the uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human primates, the unproven approach of the Company’s ImmTOR technology, our partners’ ability to re-engineer or develop any protein therapeutics, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q to be filed after this release, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release. For Investors:Bruce MackleLifeSci Advisors, LLC+1-929-469-3859bmackle@lifesciadvisors.com For Media: Brittany Leigh, Ph.D.LifeSci Communications, LLC+1-646-751-4366bleigh@lifescicomms.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880513191,"gmtCreate":1631064773813,"gmtModify":1676530456917,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Pls decrease more then more people will buy it&nbsp;","listText":"Pls decrease more then more people will buy it&nbsp;","text":"Pls decrease more then more people will buy it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880513191","repostId":"1140893024","repostType":2,"isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815540041,"gmtCreate":1630707307483,"gmtModify":1676530379166,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>up trending still continuous for this week","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>up trending still continuous for this week","text":"$Exela Technologies, Inc.(XELA)$up trending still continuous for this week","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815540041","isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815513883,"gmtCreate":1630689403142,"gmtModify":1676530378103,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Study's speed should be faster than up and down candlesticks","listText":"Study's speed should be faster than up and down candlesticks","text":"Study's speed should be faster than up and down candlesticks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815513883","repostId":"1139912608","repostType":2,"repost":{"id":"1139912608","pubTimestamp":1630454249,"share":"https://ttm.financial/m/news/1139912608?lang=&edition=fundamental","pubTime":"2021-09-01 07:57","market":"us","language":"en","title":"Here's Why Skillz Stock Suddenly Spiked Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1139912608","media":"Motley Fool","summary":"Someone just made a multimillion-dollar bet on this company.\n\nWhat happened\nShares of mobile-gaming ","content":"<blockquote>\n <b>Someone just made a multimillion-dollar bet on this company.</b>\n</blockquote>\n<p><b>What happened</b></p>\n<p>Shares of mobile-gaming platform&nbsp;<b><a href=\"https://laohu8.com/S/SKLZ\">Skillz Inc</a></b> were trading modestly higher for most of Tuesday's session. But around 1:30 p.m. EDT, the stock suddenly spiked higher, seemingly out of nowhere. As of this writing, the stock is up 12%. After a little digging, it seems that some chatter on social news platform Reddit could be responsible for the jump.</p>\n<p><b>So what</b></p>\n<p>A Reddit user posted that they had purchased $4.8 million in Skillz stock.&nbsp;Normally, I'd be reluctant to mention something like this. But there's no other news from Skillz today. Moreover, the time of the Reddit post roughly corresponds to the jump in Skillz stock. Therefore, this possibility can't be dismissed.</p>\n<p>To be clear, one Reddit user likely can't move Skillz stock this much on their own. But as we've seen with other stocks in 2021, a strong vote of confidence on Reddit can inspire many other investors to also purchase shares. And this combined effort can cause a stock to make moves.</p>\n<p><b>Now what</b></p>\n<p>Wondering if you should join the new wave of Skillz investors? I'll leave you with two thoughts. First, I wouldn't recommend ever buying or selling a stock based solely on what someone else is doing. At a minimum, you should know what the company does, and you should have a basic understanding of how its business model can create shareholder value over time.</p>\n<p>Second, remember that not everyone is playing the same game when it comes to the stock market. Someone might make a multimillion-dollar bet, but you don't know their personal financial situation or how long they plan to hold. When it comes to my approach, I'm interested in building adiversified portfolioof stocks that Ihold for many years. This strategy allows me to take advantage of the stock market's upward bias over time and also compensates for my own fallibility. This is the game I think other investors should be playing too.</p>\n<p>For the record, I'm a satisfied Skillz shareholder, and I believe it'sa company you should get to know. That said, I'd suggest investors<i>not</i>make rash buying decisions based on social media hype. If Skillz is a great long-term opportunity, it will still be there afteryou've done some research.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Skillz Stock Suddenly Spiked Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Skillz Stock Suddenly Spiked Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-01 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/31/heres-why-skillz-stock-suddenly-spiked-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Someone just made a multimillion-dollar bet on this company.\n\nWhat happened\nShares of mobile-gaming platform Skillz Inc were trading modestly higher for most of Tuesday's session. But around 1:30 p.m....</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/31/heres-why-skillz-stock-suddenly-spiked-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SKLZ":"Skillz Inc"},"source_url":"https://www.fool.com/investing/2021/08/31/heres-why-skillz-stock-suddenly-spiked-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139912608","content_text":"Someone just made a multimillion-dollar bet on this company.\n\nWhat happened\nShares of mobile-gaming platform Skillz Inc were trading modestly higher for most of Tuesday's session. But around 1:30 p.m. EDT, the stock suddenly spiked higher, seemingly out of nowhere. As of this writing, the stock is up 12%. After a little digging, it seems that some chatter on social news platform Reddit could be responsible for the jump.\nSo what\nA Reddit user posted that they had purchased $4.8 million in Skillz stock. Normally, I'd be reluctant to mention something like this. But there's no other news from Skillz today. Moreover, the time of the Reddit post roughly corresponds to the jump in Skillz stock. Therefore, this possibility can't be dismissed.\nTo be clear, one Reddit user likely can't move Skillz stock this much on their own. But as we've seen with other stocks in 2021, a strong vote of confidence on Reddit can inspire many other investors to also purchase shares. And this combined effort can cause a stock to make moves.\nNow what\nWondering if you should join the new wave of Skillz investors? I'll leave you with two thoughts. First, I wouldn't recommend ever buying or selling a stock based solely on what someone else is doing. At a minimum, you should know what the company does, and you should have a basic understanding of how its business model can create shareholder value over time.\nSecond, remember that not everyone is playing the same game when it comes to the stock market. Someone might make a multimillion-dollar bet, but you don't know their personal financial situation or how long they plan to hold. When it comes to my approach, I'm interested in building adiversified portfolioof stocks that Ihold for many years. This strategy allows me to take advantage of the stock market's upward bias over time and also compensates for my own fallibility. This is the game I think other investors should be playing too.\nFor the record, I'm a satisfied Skillz shareholder, and I believe it'sa company you should get to know. That said, I'd suggest investorsnotmake rash buying decisions based on social media hype. If Skillz is a great long-term opportunity, it will still be there afteryou've done some research.","news_type":1},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815141806,"gmtCreate":1630659906505,"gmtModify":1676530368688,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>like a coin that have two sides either long or short, it's depend on you how to anticipate...","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>like a coin that have two sides either long or short, it's depend on you how to anticipate...","text":"$Exela Technologies, Inc.(XELA)$like a coin that have two sides either long or short, it's depend on you how to anticipate...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815141806","isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571209718541642","authorId":"3571209718541642","authorIdStr":"3571209718541642","name":"Tom_Jerry","avatar":"https://static.tigerbbs.com/5ce158ae76ab06ae07b990f57e8ced26","crmLevel":2,"crmLevelSwitch":0,"idStr":"3571209718541642"},"content":"everyone wanted to buy with green. If it didn't turn to your need, either hold or retrieve.","text":"everyone wanted to buy with green. If it didn't turn to your need, either hold or retrieve.","html":"everyone wanted to buy with green. If it didn't turn to your need, either hold or retrieve."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811464961,"gmtCreate":1630337436853,"gmtModify":1676530275031,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>great job!!!","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>great job!!!","text":"$Pfizer(PFE)$great job!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/811464961","isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810014765,"gmtCreate":1629934727857,"gmtModify":1676530174506,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810014765","repostId":"2162056351","repostType":2,"repost":{"id":"2162056351","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629895654,"share":"https://ttm.financial/m/news/2162056351?lang=&edition=fundamental","pubTime":"2021-08-25 20:47","market":"us","language":"en","title":"Express Inc Stock Gains After Q2 Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2162056351","media":"Benzinga","summary":"\n","content":"<p><b><a href=\"https://laohu8.com/S/EXPR\">Express</a> Inc</b>&nbsp;(NYSE:EXPR)&nbsp;reported second-quarter FY21 sales growth of 86%&nbsp;year-on-year, to $457.6 million, beating the analyst consensus of $447.91 million.</p>\n<p>Consolidated comparable sales increased 42% versus last year and increased 3% compared to Q2 FY19.</p>\n<p>Comparable retail sales, including Express stores and eCommerce, rose 48%, and comparable outlet store sales increased 30%.</p>\n<p>E-commerce demand grew 28% Y/Y and 20% against Q2 FY19.</p>\n<p>Operating expenses rose 45.8% Y/Y.</p>\n<p>The gross margin was 32.6% versus (17.9)% last year. The gross margin expanded 580 basis points compared to Q2 FY19.</p>\n<p>The operating margin was 3.2%, and operating income for the quarter was $14.8 million against $(136.3) million in Q2 FY20.</p>\n<p>Inventory at the end of the quarter climbed 15% Y/Y to $266.6 million.</p>\n<p>The company held $33.9 million in cash and equivalents as of July 31, 2021.</p>\n<p>Cash provided by operating activities for the six months totaled $67.6 million, with a free cash flow of $57 million.</p>\n<p>EBITDA was $30.8 million versus $(118.4) million last year.</p>\n<p>Adjusted EPS of $0.02 beat the analyst consensus of $(0.30).</p>\n<p>\"We experienced an inflection point after the Fourth of July and have been driving a doubledigit comp versus 2019 since that time,\" said CEO Tim Baxter.</p>\n<p><b>Outlook</b>: Express sees net sales above 2019 levels on a comparable basis for the second half of the year.</p>\n<p><b>Price Action:</b>&nbsp;EXPR shares are trading higher by 7.85% at $7.83 in premarket on the last check Wednesday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Express Inc Stock Gains After Q2 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExpress Inc Stock Gains After Q2 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-25 20:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/EXPR\">Express</a> Inc</b>&nbsp;(NYSE:EXPR)&nbsp;reported second-quarter FY21 sales growth of 86%&nbsp;year-on-year, to $457.6 million, beating the analyst consensus of $447.91 million.</p>\n<p>Consolidated comparable sales increased 42% versus last year and increased 3% compared to Q2 FY19.</p>\n<p>Comparable retail sales, including Express stores and eCommerce, rose 48%, and comparable outlet store sales increased 30%.</p>\n<p>E-commerce demand grew 28% Y/Y and 20% against Q2 FY19.</p>\n<p>Operating expenses rose 45.8% Y/Y.</p>\n<p>The gross margin was 32.6% versus (17.9)% last year. The gross margin expanded 580 basis points compared to Q2 FY19.</p>\n<p>The operating margin was 3.2%, and operating income for the quarter was $14.8 million against $(136.3) million in Q2 FY20.</p>\n<p>Inventory at the end of the quarter climbed 15% Y/Y to $266.6 million.</p>\n<p>The company held $33.9 million in cash and equivalents as of July 31, 2021.</p>\n<p>Cash provided by operating activities for the six months totaled $67.6 million, with a free cash flow of $57 million.</p>\n<p>EBITDA was $30.8 million versus $(118.4) million last year.</p>\n<p>Adjusted EPS of $0.02 beat the analyst consensus of $(0.30).</p>\n<p>\"We experienced an inflection point after the Fourth of July and have been driving a doubledigit comp versus 2019 since that time,\" said CEO Tim Baxter.</p>\n<p><b>Outlook</b>: Express sees net sales above 2019 levels on a comparable basis for the second half of the year.</p>\n<p><b>Price Action:</b>&nbsp;EXPR shares are trading higher by 7.85% at $7.83 in premarket on the last check Wednesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXPR":"Express, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162056351","content_text":"Express Inc (NYSE:EXPR) reported second-quarter FY21 sales growth of 86% year-on-year, to $457.6 million, beating the analyst consensus of $447.91 million.\nConsolidated comparable sales increased 42% versus last year and increased 3% compared to Q2 FY19.\nComparable retail sales, including Express stores and eCommerce, rose 48%, and comparable outlet store sales increased 30%.\nE-commerce demand grew 28% Y/Y and 20% against Q2 FY19.\nOperating expenses rose 45.8% Y/Y.\nThe gross margin was 32.6% versus (17.9)% last year. The gross margin expanded 580 basis points compared to Q2 FY19.\nThe operating margin was 3.2%, and operating income for the quarter was $14.8 million against $(136.3) million in Q2 FY20.\nInventory at the end of the quarter climbed 15% Y/Y to $266.6 million.\nThe company held $33.9 million in cash and equivalents as of July 31, 2021.\nCash provided by operating activities for the six months totaled $67.6 million, with a free cash flow of $57 million.\nEBITDA was $30.8 million versus $(118.4) million last year.\nAdjusted EPS of $0.02 beat the analyst consensus of $(0.30).\n\"We experienced an inflection point after the Fourth of July and have been driving a doubledigit comp versus 2019 since that time,\" said CEO Tim Baxter.\nOutlook: Express sees net sales above 2019 levels on a comparable basis for the second half of the year.\nPrice Action: EXPR shares are trading higher by 7.85% at $7.83 in premarket on the last check Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835479286,"gmtCreate":1629736159645,"gmtModify":1676530117220,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>cmon up up&nbsp;","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>cmon up up&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$cmon up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835479286","isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":800486861,"gmtCreate":1627312469953,"gmtModify":1703487468595,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>down to 330","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>down to 330","text":"$Moderna, Inc.(MRNA)$down to 330","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/800486861","isVote":1,"tweetType":1,"viewCount":889,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3577133427484090","authorId":"3577133427484090","authorIdStr":"3577133427484090","name":"Eunuch太监","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3577133427484090"},"content":"This stock being manipulated","text":"This stock being manipulated","html":"This stock being manipulated"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179129089,"gmtCreate":1626494628741,"gmtModify":1703761128798,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Pfizer price just started to climb, hmmmm....","listText":"Pfizer price just started to climb, hmmmm....","text":"Pfizer price just started to climb, hmmmm....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/179129089","repostId":"2152168563","repostType":4,"isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179164504,"gmtCreate":1626494445608,"gmtModify":1703761125998,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Most of the stocks will experience the same, in a matter of time, pls find your own good time to buy the dip and release it before start to squeeze.","listText":"Most of the stocks will experience the same, in a matter of time, pls find your own good time to buy the dip and release it before start to squeeze.","text":"Most of the stocks will experience the same, in a matter of time, pls find your own good time to buy the dip and release it before start to squeeze.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/179164504","repostId":"1159574501","repostType":4,"repost":{"id":"1159574501","pubTimestamp":1626484131,"share":"https://ttm.financial/m/news/1159574501?lang=&edition=fundamental","pubTime":"2021-07-17 09:08","market":"us","language":"en","title":"'Bad Omen' For Meme Stocks And The Retail Trading Boom? Here's What The Data Says","url":"https://stock-news.laohu8.com/highlight/detail?id=1159574501","media":"Benzinga","summary":"Social media meme stocks GameStop Corp.(NYSE:GME) and AMC Entertainment Holdings Inc(NYSE:AMC) took ","content":"<p>Social media meme stocks&nbsp;<b>GameStop Corp.</b>(NYSE:GME) and&nbsp;<b>AMC Entertainment Holdings Inc</b>(NYSE:AMC) took a beating this week, with GameStop on track to finish the week down 9% and AMC set to lose 20.9% in Friday afternoon trading.</p>\n<p>DataTrek Research co-founder Nicholas Colas said this week&nbsp;there is an ominous sign the&nbsp;meme stock phenomenon may be dying a slow death.</p>\n<p><b>Retail Trading Boom:</b>DataTrek has been periodically tracking the boom in retail traders triggered during the pandemic in 2020 and 2021 by monitoring U.S. Google search volume for the keywords “invest” and “buy stock.” Colas said these basic search terms are a broad way to gauge marginal retail investor interest in the stock market.</p>\n<p>The image below shows how search volume for those key phrases has changed since the beginning of 2020.</p>\n<p><img src=\"https://static.tigerbbs.com/9930646712b9790171cccf12a873f757\" tg-width=\"1199\" tg-height=\"560\" referrerpolicy=\"no-referrer\"></p>\n<p>Colas said the search volume data clearly indicates the retail stock trading fad is completely over at this point, a “very bad omen” for AMC and GameStop. In fact, Google search volume is now back down to where it was before the pandemic started in early 2020.</p>\n<p>In addition, search volumes are now down 75% from their peak levels during the initial short squeezes in AMC and GameStop back in January 2021.</p>\n<p>Colas said meme stocks like AMC need new retail stock traders to join in the buying to support their stock prices else they could be headed for more volatility like they have experienced this week.</p>\n<p>“Bubbles need fresh money, or they deflate. Quickly,” Colas wrote. “Every craze needs new adherents (i.e., not just the same crowd) to keep it relevant, and the Google chart shows those are in increasingly short supply.”</p>\n<p><b>PMP Weighs In:</b>Benzinga&nbsp;PreMarket Prep co-host Dennis Dick said&nbsp;a good story can carry a stock a long way, and some stocks can even become so hot that they become temporarily disconnected from the company’s underlying fundamentals.</p>\n<p>“We have seen that in a number of meme stocks this year. Story can drive price in the short run but stocks almost always return back to their fundamental value in the long run,” Dick said.</p>\n<p>The type of disconnect between share price and underlying value that AMC and GameStop have experienced in 2021 is certainly nothing new. Canadian cannabis stock&nbsp;<b>Tilray Inc</b>(NASDAQ:TLRY) experienced a similar disconnect back in 2018 when a retail stock mania sent the stock skyrocketing up to $300. Today, Tilray is trading back down at around $13.90.</p>\n<p>“As the stock price begins to fall, momentum traders who have been chasing the hot story will begin to exit. But if the stock trades at an extreme valuation, there may be very few traders willing to buy. This is what we are starting to see in many meme stocks today,” Dick said.</p>\n<p><b>Benzinga's Take:</b>If the story begins to get hot again, the stock prices of overvalued story stocks can always recover once again. But without any underlying fundamentals to support the valuation, these types of stocks need a constant stream of new buyers and an increasingly bullish story to generate fresh enthusiasm.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>'Bad Omen' For Meme Stocks And The Retail Trading Boom? Here's What The Data Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n'Bad Omen' For Meme Stocks And The Retail Trading Boom? Here's What The Data Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-17 09:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22023662/bad-omen-for-meme-stocks-and-the-retail-trading-boom-heres-what-the-data-says><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Social media meme stocks GameStop Corp.(NYSE:GME) and AMC Entertainment Holdings Inc(NYSE:AMC) took a beating this week, with GameStop on track to finish the week down 9% and AMC set to lose 20.9% in ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22023662/bad-omen-for-meme-stocks-and-the-retail-trading-boom-heres-what-the-data-says\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","TLRY":"Tilray Inc.","AMC":"AMC院线"},"source_url":"https://www.benzinga.com/analyst-ratings/analyst-color/21/07/22023662/bad-omen-for-meme-stocks-and-the-retail-trading-boom-heres-what-the-data-says","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159574501","content_text":"Social media meme stocks GameStop Corp.(NYSE:GME) and AMC Entertainment Holdings Inc(NYSE:AMC) took a beating this week, with GameStop on track to finish the week down 9% and AMC set to lose 20.9% in Friday afternoon trading.\nDataTrek Research co-founder Nicholas Colas said this week there is an ominous sign the meme stock phenomenon may be dying a slow death.\nRetail Trading Boom:DataTrek has been periodically tracking the boom in retail traders triggered during the pandemic in 2020 and 2021 by monitoring U.S. Google search volume for the keywords “invest” and “buy stock.” Colas said these basic search terms are a broad way to gauge marginal retail investor interest in the stock market.\nThe image below shows how search volume for those key phrases has changed since the beginning of 2020.\n\nColas said the search volume data clearly indicates the retail stock trading fad is completely over at this point, a “very bad omen” for AMC and GameStop. In fact, Google search volume is now back down to where it was before the pandemic started in early 2020.\nIn addition, search volumes are now down 75% from their peak levels during the initial short squeezes in AMC and GameStop back in January 2021.\nColas said meme stocks like AMC need new retail stock traders to join in the buying to support their stock prices else they could be headed for more volatility like they have experienced this week.\n“Bubbles need fresh money, or they deflate. Quickly,” Colas wrote. “Every craze needs new adherents (i.e., not just the same crowd) to keep it relevant, and the Google chart shows those are in increasingly short supply.”\nPMP Weighs In:Benzinga PreMarket Prep co-host Dennis Dick said a good story can carry a stock a long way, and some stocks can even become so hot that they become temporarily disconnected from the company’s underlying fundamentals.\n“We have seen that in a number of meme stocks this year. Story can drive price in the short run but stocks almost always return back to their fundamental value in the long run,” Dick said.\nThe type of disconnect between share price and underlying value that AMC and GameStop have experienced in 2021 is certainly nothing new. Canadian cannabis stock Tilray Inc(NASDAQ:TLRY) experienced a similar disconnect back in 2018 when a retail stock mania sent the stock skyrocketing up to $300. Today, Tilray is trading back down at around $13.90.\n“As the stock price begins to fall, momentum traders who have been chasing the hot story will begin to exit. But if the stock trades at an extreme valuation, there may be very few traders willing to buy. This is what we are starting to see in many meme stocks today,” Dick said.\nBenzinga's Take:If the story begins to get hot again, the stock prices of overvalued story stocks can always recover once again. But without any underlying fundamentals to support the valuation, these types of stocks need a constant stream of new buyers and an increasingly bullish story to generate fresh enthusiasm.","news_type":1},"isVote":1,"tweetType":1,"viewCount":6,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144410685,"gmtCreate":1626309706247,"gmtModify":1703757523969,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>this drop will results more explosive to the upside.","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>this drop will results more explosive to the upside.","text":"$Exela Technologies, Inc.(XELA)$this drop will results more explosive to the upside.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/144410685","isVote":1,"tweetType":1,"viewCount":96,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147548474,"gmtCreate":1626367300898,"gmtModify":1703758877527,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>no one knows what is the closing n highest&nbsp;price, just wait n see or close it then come back in 3hrs time ;)","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>no one knows what is the closing n highest&nbsp;price, just wait n see or close it then come back in 3hrs time ;)","text":"$Exela Technologies, Inc.(XELA)$no one knows what is the closing n highest price, just wait n see or close it then come back in 3hrs time ;)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147548474","isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154860934,"gmtCreate":1625498321328,"gmtModify":1703742740363,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/154860934","repostId":"1166963826","repostType":4,"repost":{"id":"1166963826","pubTimestamp":1625486061,"share":"https://ttm.financial/m/news/1166963826?lang=&edition=fundamental","pubTime":"2021-07-05 19:54","market":"us","language":"en","title":"US IPO This Week: Just 2 IPOs scheduled for the shortened holiday week","url":"https://stock-news.laohu8.com/highlight/detail?id=1166963826","media":"renaissancecap...","summary":"Following its busiest week in over a decade, the US IPO market is taking a breather after the holida","content":"<p>Following its busiest week in over a decade, the US IPO market is taking a breather after the holiday with just two IPOs scheduled for the shortened week ahead.</p>\n<p>While the calendar is quiet at the moment, several companies are primed to launch, including luxury social club&nbsp;<b>Membership Collective Group</b>(MCG), Wahlberg-backed fitness franchise&nbsp;<b>F45 Training</b>(FXLV), database provider&nbsp;<b>Couchbase</b>(BASE), and consumer banking platform<b>BlendLabs</b>(BLND).</p>\n<p>Chinese healthcare data company&nbsp;<b>LinkDoc Technology</b>(LDOC) plans to raise $200 million at a $1.5 billion market cap. This AI-driven healthcare technology company provides a data platform for patient care and clinical research, specifically within oncology. Unprofitable with strong growth, LinkDoc's platform has cumulatively cared for over 3.5 million patients and provided longitudinal care for over 2.5 million patients since 2015.</p>\n<p>OTC-list&nbsp;<b>Minim</b>(MINM), which provides intelligent networking products and a WiFi as a Service platform, has not set terms but plans to begin trading in the week ahead.&nbsp;Minim has developed intelligent networking products and a WiFi as a Service platform that powers applications for businesses, service providers, and home users. The company's products can be found in retailers across the US and in over 100 Internet Service Providers broadband offerings.</p>\n<p><img src=\"https://static.tigerbbs.com/003a0748043153c660ff267811776609\" tg-width=\"1421\" tg-height=\"362\" referrerpolicy=\"no-referrer\"></p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO This Week: Just 2 IPOs scheduled for the shortened holiday week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO This Week: Just 2 IPOs scheduled for the shortened holiday week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 19:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/83625/US-IPO-Week-Ahead-Just-2-IPOs-scheduled-for-the-shortened-holiday-week><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Following its busiest week in over a decade, the US IPO market is taking a breather after the holiday with just two IPOs scheduled for the shortened week ahead.\nWhile the calendar is quiet at the ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/83625/US-IPO-Week-Ahead-Just-2-IPOs-scheduled-for-the-shortened-holiday-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MINM":"Minim Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/83625/US-IPO-Week-Ahead-Just-2-IPOs-scheduled-for-the-shortened-holiday-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166963826","content_text":"Following its busiest week in over a decade, the US IPO market is taking a breather after the holiday with just two IPOs scheduled for the shortened week ahead.\nWhile the calendar is quiet at the moment, several companies are primed to launch, including luxury social club Membership Collective Group(MCG), Wahlberg-backed fitness franchise F45 Training(FXLV), database provider Couchbase(BASE), and consumer banking platformBlendLabs(BLND).\nChinese healthcare data company LinkDoc Technology(LDOC) plans to raise $200 million at a $1.5 billion market cap. This AI-driven healthcare technology company provides a data platform for patient care and clinical research, specifically within oncology. Unprofitable with strong growth, LinkDoc's platform has cumulatively cared for over 3.5 million patients and provided longitudinal care for over 2.5 million patients since 2015.\nOTC-list Minim(MINM), which provides intelligent networking products and a WiFi as a Service platform, has not set terms but plans to begin trading in the week ahead. Minim has developed intelligent networking products and a WiFi as a Service platform that powers applications for businesses, service providers, and home users. The company's products can be found in retailers across the US and in over 100 Internet Service Providers broadband offerings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":29,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152184533,"gmtCreate":1625276100122,"gmtModify":1703739760646,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>i think &nbsp;$20 - $30 will be open price at HK shares","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>i think &nbsp;$20 - $30 will be open price at HK shares","text":"$XPeng Inc.(XPEV)$i think $20 - $30 will be open price at HK shares","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/152184533","isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559463359065359","authorId":"3559463359065359","authorIdStr":"3559463359065359","name":"ArkInvest","avatar":"https://static.tigerbbs.com/6dfcf7df27430673110d69ba1374e540","crmLevel":2,"crmLevelSwitch":0,"idStr":"3559463359065359"},"content":"it will rise to the moon","text":"it will rise to the moon","html":"it will rise to the moon"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156096292,"gmtCreate":1625184996416,"gmtModify":1703737806616,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/156096292","repostId":"2148276938","repostType":2,"repost":{"id":"2148276938","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625184352,"share":"https://ttm.financial/m/news/2148276938?lang=&edition=fundamental","pubTime":"2021-07-02 08:05","market":"hk","language":"en","title":"China's Xpeng to be added to FTSE's equity indexes on July 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2148276938","media":"Reuters","summary":"SHANGHAI, July 2  - Chinese electric vehicle maker Xpeng's American Depositary Receipts will be added to FTSE Russell's global equity indexes on July 8, the index publisher said.Xpeng shares will be included in the FTSE All-World Index, the FTSE Global Large Cap Index, and the FTSE Emerging Index, FTSE Russell said in a statement on its website.The announcement came after Guangzhou-based Xpeng said on Wednesday it would raise $1.8 billion in a Hong Kong dual primary listing to expand its product","content":"<p>SHANGHAI, July 2 (Reuters) - Chinese electric vehicle maker Xpeng's American Depositary Receipts will be added to FTSE Russell's global equity indexes on July 8, the index publisher said.</p>\n<p>Xpeng shares will be included in the FTSE All-World Index, the FTSE Global Large Cap Index, and the FTSE Emerging Index, FTSE Russell said in a statement on its website.</p>\n<p>The announcement came after Guangzhou-based Xpeng said on Wednesday it would raise $1.8 billion in a Hong Kong dual primary listing to expand its product line-up and develop its technology.</p>\n<p>The company said on Thursday that it delivered 17,398 vehicles in the second quarter, a five-fold increase from a year earlier.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Xpeng to be added to FTSE's equity indexes on July 8</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Xpeng to be added to FTSE's equity indexes on July 8\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-02 08:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANGHAI, July 2 (Reuters) - Chinese electric vehicle maker Xpeng's American Depositary Receipts will be added to FTSE Russell's global equity indexes on July 8, the index publisher said.</p>\n<p>Xpeng shares will be included in the FTSE All-World Index, the FTSE Global Large Cap Index, and the FTSE Emerging Index, FTSE Russell said in a statement on its website.</p>\n<p>The announcement came after Guangzhou-based Xpeng said on Wednesday it would raise $1.8 billion in a Hong Kong dual primary listing to expand its product line-up and develop its technology.</p>\n<p>The company said on Thursday that it delivered 17,398 vehicles in the second quarter, a five-fold increase from a year earlier.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","09868":"小鹏汽车-W"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148276938","content_text":"SHANGHAI, July 2 (Reuters) - Chinese electric vehicle maker Xpeng's American Depositary Receipts will be added to FTSE Russell's global equity indexes on July 8, the index publisher said.\nXpeng shares will be included in the FTSE All-World Index, the FTSE Global Large Cap Index, and the FTSE Emerging Index, FTSE Russell said in a statement on its website.\nThe announcement came after Guangzhou-based Xpeng said on Wednesday it would raise $1.8 billion in a Hong Kong dual primary listing to expand its product line-up and develop its technology.\nThe company said on Thursday that it delivered 17,398 vehicles in the second quarter, a five-fold increase from a year earlier.","news_type":1},"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800573899,"gmtCreate":1627310066611,"gmtModify":1703487394603,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>highest 2.59","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>highest 2.59","text":"$Exela Technologies, Inc.(XELA)$highest 2.59","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/800573899","isVote":1,"tweetType":1,"viewCount":796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175776803,"gmtCreate":1627050919002,"gmtModify":1703483398464,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EDU\">$New Oriental Education &amp; Technology(EDU)$</a>strange... Buying in low price with big qty","listText":"<a href=\"https://laohu8.com/S/EDU\">$New Oriental Education &amp; Technology(EDU)$</a>strange... Buying in low price with big qty","text":"$New Oriental Education & Technology(EDU)$strange... Buying in low price with big qty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/175776803","isVote":1,"tweetType":1,"viewCount":2735,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3575203465272475","authorId":"3575203465272475","authorIdStr":"3575203465272475","name":"Randomtrader","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":1,"idStr":"3575203465272475"},"content":"they are indeed dumb, Im shorting it till 1.90","text":"they are indeed dumb, Im shorting it till 1.90","html":"they are indeed dumb, Im shorting it till 1.90"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144222939,"gmtCreate":1626302541221,"gmtModify":1703757292688,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>you bought at $2 then now fall from $4 to $3 and you are screaming like hell, what a joke.","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>you bought at $2 then now fall from $4 to $3 and you are screaming like hell, what a joke.","text":"$Exela Technologies, Inc.(XELA)$you bought at $2 then now fall from $4 to $3 and you are screaming like hell, what a joke.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/144222939","isVote":1,"tweetType":1,"viewCount":45,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880513191,"gmtCreate":1631064773813,"gmtModify":1676530456917,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Pls decrease more then more people will buy it&nbsp;","listText":"Pls decrease more then more people will buy it&nbsp;","text":"Pls decrease more then more people will buy it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880513191","repostId":"1140893024","repostType":2,"repost":{"id":"1140893024","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631054373,"share":"https://ttm.financial/m/news/1140893024?lang=&edition=fundamental","pubTime":"2021-09-08 06:39","market":"us","language":"en","title":"Nio shares fall after $2 billion stock offering announced","url":"https://stock-news.laohu8.com/highlight/detail?id=1140893024","media":"Tiger Newspress","summary":"NIO shares slipped 3.5% in extended trading after announcing at-the-market offering of American depo","content":"<p>NIO shares slipped 3.5% in extended trading&nbsp;after&nbsp;announcing at-the-market offering of American depositary shares.</p>\n<p><img src=\"https://static.tigerbbs.com/e0907d5351eb6acc6316886c6ac37011\" tg-width=\"890\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p>\n<p>NIO Inc. announced that it has filed a prospectus supplement to sell up to an aggregate of US$2,000,000,000 of its American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company, through an at-the-market equity offering program (the “At-The-Market Offering”).</p>\n<p>The ADSs will be offered through Credit Suisse Securities (USA) LLC, Morgan Stanley &amp; Co. LLC, Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, Nomura Securities International, Inc. and Guotai Junan Securities (Hong Kong) Limited as sales agents. Some of the sales agents are expected to make offers and sales both inside and outside the United States through their respective selling agents.</p>\n<p>NIO has entered into an equity distribution agreement with the sales agents relating to the At-The-Market Offering. Sales, if any, of the ADSs under the At-The-Market Offering will be made from time to time, at the Company’s discretion, by means of ordinary broker transactions on or through the New York Stock Exchange (the “NYSE”) or other markets for its ADSs, sales made to or through a market maker other than on an exchange, or otherwise in negotiated transactions, or as otherwise agreed with the sales agents. Sales may be made at market prices prevailing at the time of sale or at negotiated prices. As a result, sales prices may vary.</p>\n<p>The Company currently plans to use the net proceeds from the At-The-Market Offering to further strengthen its balance sheet, as well as for general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio shares fall after $2 billion stock offering announced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio shares fall after $2 billion stock offering announced\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-08 06:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NIO shares slipped 3.5% in extended trading&nbsp;after&nbsp;announcing at-the-market offering of American depositary shares.</p>\n<p><img src=\"https://static.tigerbbs.com/e0907d5351eb6acc6316886c6ac37011\" tg-width=\"890\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p>\n<p>NIO Inc. announced that it has filed a prospectus supplement to sell up to an aggregate of US$2,000,000,000 of its American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company, through an at-the-market equity offering program (the “At-The-Market Offering”).</p>\n<p>The ADSs will be offered through Credit Suisse Securities (USA) LLC, Morgan Stanley &amp; Co. LLC, Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, Nomura Securities International, Inc. and Guotai Junan Securities (Hong Kong) Limited as sales agents. Some of the sales agents are expected to make offers and sales both inside and outside the United States through their respective selling agents.</p>\n<p>NIO has entered into an equity distribution agreement with the sales agents relating to the At-The-Market Offering. Sales, if any, of the ADSs under the At-The-Market Offering will be made from time to time, at the Company’s discretion, by means of ordinary broker transactions on or through the New York Stock Exchange (the “NYSE”) or other markets for its ADSs, sales made to or through a market maker other than on an exchange, or otherwise in negotiated transactions, or as otherwise agreed with the sales agents. Sales may be made at market prices prevailing at the time of sale or at negotiated prices. As a result, sales prices may vary.</p>\n<p>The Company currently plans to use the net proceeds from the At-The-Market Offering to further strengthen its balance sheet, as well as for general corporate purposes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140893024","content_text":"NIO shares slipped 3.5% in extended trading after announcing at-the-market offering of American depositary shares.\n\nNIO Inc. announced that it has filed a prospectus supplement to sell up to an aggregate of US$2,000,000,000 of its American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company, through an at-the-market equity offering program (the “At-The-Market Offering”).\nThe ADSs will be offered through Credit Suisse Securities (USA) LLC, Morgan Stanley & Co. LLC, Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, Nomura Securities International, Inc. and Guotai Junan Securities (Hong Kong) Limited as sales agents. Some of the sales agents are expected to make offers and sales both inside and outside the United States through their respective selling agents.\nNIO has entered into an equity distribution agreement with the sales agents relating to the At-The-Market Offering. Sales, if any, of the ADSs under the At-The-Market Offering will be made from time to time, at the Company’s discretion, by means of ordinary broker transactions on or through the New York Stock Exchange (the “NYSE”) or other markets for its ADSs, sales made to or through a market maker other than on an exchange, or otherwise in negotiated transactions, or as otherwise agreed with the sales agents. Sales may be made at market prices prevailing at the time of sale or at negotiated prices. As a result, sales prices may vary.\nThe Company currently plans to use the net proceeds from the At-The-Market Offering to further strengthen its balance sheet, as well as for general corporate purposes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":62,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805369082,"gmtCreate":1627861438046,"gmtModify":1703496587406,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805369082","repostId":"1170689665","repostType":4,"repost":{"id":"1170689665","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627857540,"share":"https://ttm.financial/m/news/1170689665?lang=&edition=fundamental","pubTime":"2021-08-02 06:39","market":"us","language":"en","title":"Alibaba,Uber, DraftKings, GM, Roku, EA, ViacomCBS, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1170689665","media":"Tiger Newspress","summary":"The parade of second-quarter results continues this week. No fewer than 143 S&P 500 companies are on deck to report, in addition to hundreds of small caps. Ferrari, Vornado Realty Trust, Take-Two Interactive Software, and Simon Property Group will get the ball rolling on Monday. Then Lyft, Alibaba Group Holding, Nikola, Under Armour, Eli Lilly, and ConocoPhillips release their results on Tuesday.Wednesday will be particularly busy:General Motors,Uber Technologies,Etsy,Electronic Arts,Western Dig","content":"<p>The parade of second-quarter results continues this week. No fewer than 143 S&amp;P 500 companies are on deck to report, in addition to hundreds of small caps. Ferrari, Vornado Realty Trust, Take-Two Interactive Software, and Simon Property Group will get the ball rolling on Monday. Then Lyft, Alibaba Group Holding, Nikola, Under Armour, Eli Lilly, and ConocoPhillips release their results on Tuesday.</p>\n<p>Wednesday will be particularly busy:General Motors,Uber Technologies,Etsy,Electronic Arts,Western Digital,Roku,CVS Health,Kraft Heinz, and SoftBank all report.Beyond Meat,Yelp,Wayfair, Moderna, and&nbsp;ViacomCBS&nbsp;go on Thursday and&nbsp;DraftKings,Canopy Growth,and Tripadvisor will close the week on Friday.Chinese Education Corporation&nbsp;New Oriental Education &amp; Technology Group Inc. and&nbsp;TAL Education Group&nbsp;cancels scheduled earnings release and earnings call.</p>\n<p><img src=\"https://static.tigerbbs.com/94057bf11ca8d7311db6c075ba98727b\" tg-width=\"1706\" tg-height=\"740\" referrerpolicy=\"no-referrer\"></p>\n<p>The highlight on the&nbsp;economic&nbsp;calendar this week will be Jobs Friday. The Bureau of Labor Statistics is expected to show a gain of 625,000 nonfarm payrolls in July, following June’s 850,000. The unemployment rate is seen holding just below 6%.</p>\n<p>Other data out this week include the Institute for Supply Management’s Manufacturing Purchasing Managers’ Index for July on Monday, followed by the Services equivalent on Wednesday. Both measures of economic activity are forecast to come in at around 61, which would signify strong expansion.</p>\n<p><b>Monday 8/2</b></p>\n<p>CNA Financial,Global Payments,JELD-WEN Holding,Loews,Arista Networks,Leggett &amp; Platt,Vornado Realty Trust, ZoomInfo Technologies, Woodward, Take-Two Interactive Software, Heineken, Trex, Ferrari,Ultra Clean Holdings,and Simon Property Group are expected to release financial results.</p>\n<p>GE stock&nbsp;will open for trading Monday at about $104 a share, after closing Friday at $12.95. The company completed its 1-for-8 reverse stock split Friday evening.</p>\n<p><b>The Institute for Supply</b>&nbsp;Management releases its Manufacturing Purchasing Managers’ Index for July. Consensus estimate is for a 60.8 reading, up from 60.6 in June.</p>\n<p><b>The Census Bureau</b>&nbsp;reports construction spending for June. Expectations are for a 0.4% month-over-month rise, after a 0.3% decline in May.</p>\n<p><b>Tuesday 8/3</b></p>\n<p>Eaton, BP, Under Armour, Lyft,Clorox,Amgen,Akamai Technologies,Cummins, Eli Lilly, Alibaba Group Holding, Nikola, EnPro Industries,Warner Music Group,Pitney Bowes,Tennant,Phillips 66,KKR,Gartner,Henry Schein,Dun &amp; Bradstreet Holdings,ConocoPhillips, and&nbsp;Jacobs Engineering Grouphost conference calls to discuss financial results.</p>\n<p><b>The Census Bureau</b>&nbsp;is slated to report factory orders for June. Economists predict that orders increased 1.0% during the month, compared with a 1.7% rise in May.</p>\n<p><b>Wednesday 8/4</b></p>\n<p>Sony Group,CVS Health, Kraft Heinz, SoftBank, General Motors, Progressive, Etsy, Electronic Arts, Western Digital, Uber Technologies, Roku,MGM Resorts International,Fox, and Re/Max Holdings are expected to host earnings calls.</p>\n<p><b>The Bureau of Economic</b>&nbsp;Analysis reports light-vehicle sales for July. Expectations call for a seasonally adjusted annual rate of 15.3 million vehicles, versus 15.4 million in June.</p>\n<p><b>The ISM releases</b>&nbsp;its Services PMI for July. Consensus estimate is for a 60.8 reading, compared with June’s 60.1.</p>\n<p><b>ADP releases</b>&nbsp;its National Employment report for July. Consensus estimate is for a 635,000 gain in nonfarm private-sector employment, following an increase of 692,000 in June.</p>\n<p><b>Thursday 8/5</b></p>\n<p>Zillow Group,Beyond Meat, Yelp, Wayfair, Kellogg,Bayer,HanesBrands, Moderna,Regeneron Pharmaceuticals,Switch,Cushman &amp; Wakefield,ViacomCBS,Cigna,Duke Energy,Square,News Corp,and&nbsp;Siemensare expected to report financial results.</p>\n<p>Friday 8/6</p>\n<p><b>The BLS releases the jobs report</b>&nbsp;for July. Economists forecast a 800,000 rise in nonfarm payrolls, after an 850,000 gain in June. The unemployment rate is expected to edge down to 5.8% from 5.9%.</p>\n<p>DraftKings,Dominion Energy,Gannett,MGM Growth Properties,AMC Networks,Canopy Growth, Tripadvisor,Spectrum Brands Holdings,E.W. Scripps,Cinemark Holdings, and Manitowoc host conference calls to discuss financial results.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba,Uber, DraftKings, GM, Roku, EA, ViacomCBS, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba,Uber, DraftKings, GM, Roku, EA, ViacomCBS, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 06:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The parade of second-quarter results continues this week. No fewer than 143 S&amp;P 500 companies are on deck to report, in addition to hundreds of small caps. Ferrari, Vornado Realty Trust, Take-Two Interactive Software, and Simon Property Group will get the ball rolling on Monday. Then Lyft, Alibaba Group Holding, Nikola, Under Armour, Eli Lilly, and ConocoPhillips release their results on Tuesday.</p>\n<p>Wednesday will be particularly busy:General Motors,Uber Technologies,Etsy,Electronic Arts,Western Digital,Roku,CVS Health,Kraft Heinz, and SoftBank all report.Beyond Meat,Yelp,Wayfair, Moderna, and&nbsp;ViacomCBS&nbsp;go on Thursday and&nbsp;DraftKings,Canopy Growth,and Tripadvisor will close the week on Friday.Chinese Education Corporation&nbsp;New Oriental Education &amp; Technology Group Inc. and&nbsp;TAL Education Group&nbsp;cancels scheduled earnings release and earnings call.</p>\n<p><img src=\"https://static.tigerbbs.com/94057bf11ca8d7311db6c075ba98727b\" tg-width=\"1706\" tg-height=\"740\" referrerpolicy=\"no-referrer\"></p>\n<p>The highlight on the&nbsp;economic&nbsp;calendar this week will be Jobs Friday. The Bureau of Labor Statistics is expected to show a gain of 625,000 nonfarm payrolls in July, following June’s 850,000. The unemployment rate is seen holding just below 6%.</p>\n<p>Other data out this week include the Institute for Supply Management’s Manufacturing Purchasing Managers’ Index for July on Monday, followed by the Services equivalent on Wednesday. Both measures of economic activity are forecast to come in at around 61, which would signify strong expansion.</p>\n<p><b>Monday 8/2</b></p>\n<p>CNA Financial,Global Payments,JELD-WEN Holding,Loews,Arista Networks,Leggett &amp; Platt,Vornado Realty Trust, ZoomInfo Technologies, Woodward, Take-Two Interactive Software, Heineken, Trex, Ferrari,Ultra Clean Holdings,and Simon Property Group are expected to release financial results.</p>\n<p>GE stock&nbsp;will open for trading Monday at about $104 a share, after closing Friday at $12.95. The company completed its 1-for-8 reverse stock split Friday evening.</p>\n<p><b>The Institute for Supply</b>&nbsp;Management releases its Manufacturing Purchasing Managers’ Index for July. Consensus estimate is for a 60.8 reading, up from 60.6 in June.</p>\n<p><b>The Census Bureau</b>&nbsp;reports construction spending for June. Expectations are for a 0.4% month-over-month rise, after a 0.3% decline in May.</p>\n<p><b>Tuesday 8/3</b></p>\n<p>Eaton, BP, Under Armour, Lyft,Clorox,Amgen,Akamai Technologies,Cummins, Eli Lilly, Alibaba Group Holding, Nikola, EnPro Industries,Warner Music Group,Pitney Bowes,Tennant,Phillips 66,KKR,Gartner,Henry Schein,Dun &amp; Bradstreet Holdings,ConocoPhillips, and&nbsp;Jacobs Engineering Grouphost conference calls to discuss financial results.</p>\n<p><b>The Census Bureau</b>&nbsp;is slated to report factory orders for June. Economists predict that orders increased 1.0% during the month, compared with a 1.7% rise in May.</p>\n<p><b>Wednesday 8/4</b></p>\n<p>Sony Group,CVS Health, Kraft Heinz, SoftBank, General Motors, Progressive, Etsy, Electronic Arts, Western Digital, Uber Technologies, Roku,MGM Resorts International,Fox, and Re/Max Holdings are expected to host earnings calls.</p>\n<p><b>The Bureau of Economic</b>&nbsp;Analysis reports light-vehicle sales for July. Expectations call for a seasonally adjusted annual rate of 15.3 million vehicles, versus 15.4 million in June.</p>\n<p><b>The ISM releases</b>&nbsp;its Services PMI for July. Consensus estimate is for a 60.8 reading, compared with June’s 60.1.</p>\n<p><b>ADP releases</b>&nbsp;its National Employment report for July. Consensus estimate is for a 635,000 gain in nonfarm private-sector employment, following an increase of 692,000 in June.</p>\n<p><b>Thursday 8/5</b></p>\n<p>Zillow Group,Beyond Meat, Yelp, Wayfair, Kellogg,Bayer,HanesBrands, Moderna,Regeneron Pharmaceuticals,Switch,Cushman &amp; Wakefield,ViacomCBS,Cigna,Duke Energy,Square,News Corp,and&nbsp;Siemensare expected to report financial results.</p>\n<p>Friday 8/6</p>\n<p><b>The BLS releases the jobs report</b>&nbsp;for July. Economists forecast a 800,000 rise in nonfarm payrolls, after an 850,000 gain in June. The unemployment rate is expected to edge down to 5.8% from 5.9%.</p>\n<p>DraftKings,Dominion Energy,Gannett,MGM Growth Properties,AMC Networks,Canopy Growth, Tripadvisor,Spectrum Brands Holdings,E.W. Scripps,Cinemark Holdings, and Manitowoc host conference calls to discuss financial results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","EA":"艺电","DKNG":"DraftKings Inc.",".SPX":"S&P 500 Index","ROKU":"Roku Inc","UBER":"优步","GM":"通用汽车",".DJI":"道琼斯","GE":"GE航空航天","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170689665","content_text":"The parade of second-quarter results continues this week. No fewer than 143 S&P 500 companies are on deck to report, in addition to hundreds of small caps. Ferrari, Vornado Realty Trust, Take-Two Interactive Software, and Simon Property Group will get the ball rolling on Monday. Then Lyft, Alibaba Group Holding, Nikola, Under Armour, Eli Lilly, and ConocoPhillips release their results on Tuesday.\nWednesday will be particularly busy:General Motors,Uber Technologies,Etsy,Electronic Arts,Western Digital,Roku,CVS Health,Kraft Heinz, and SoftBank all report.Beyond Meat,Yelp,Wayfair, Moderna, and ViacomCBS go on Thursday and DraftKings,Canopy Growth,and Tripadvisor will close the week on Friday.Chinese Education Corporation New Oriental Education & Technology Group Inc. and TAL Education Group cancels scheduled earnings release and earnings call.\n\nThe highlight on the economic calendar this week will be Jobs Friday. The Bureau of Labor Statistics is expected to show a gain of 625,000 nonfarm payrolls in July, following June’s 850,000. The unemployment rate is seen holding just below 6%.\nOther data out this week include the Institute for Supply Management’s Manufacturing Purchasing Managers’ Index for July on Monday, followed by the Services equivalent on Wednesday. Both measures of economic activity are forecast to come in at around 61, which would signify strong expansion.\nMonday 8/2\nCNA Financial,Global Payments,JELD-WEN Holding,Loews,Arista Networks,Leggett & Platt,Vornado Realty Trust, ZoomInfo Technologies, Woodward, Take-Two Interactive Software, Heineken, Trex, Ferrari,Ultra Clean Holdings,and Simon Property Group are expected to release financial results.\nGE stock will open for trading Monday at about $104 a share, after closing Friday at $12.95. The company completed its 1-for-8 reverse stock split Friday evening.\nThe Institute for Supply Management releases its Manufacturing Purchasing Managers’ Index for July. Consensus estimate is for a 60.8 reading, up from 60.6 in June.\nThe Census Bureau reports construction spending for June. Expectations are for a 0.4% month-over-month rise, after a 0.3% decline in May.\nTuesday 8/3\nEaton, BP, Under Armour, Lyft,Clorox,Amgen,Akamai Technologies,Cummins, Eli Lilly, Alibaba Group Holding, Nikola, EnPro Industries,Warner Music Group,Pitney Bowes,Tennant,Phillips 66,KKR,Gartner,Henry Schein,Dun & Bradstreet Holdings,ConocoPhillips, and Jacobs Engineering Grouphost conference calls to discuss financial results.\nThe Census Bureau is slated to report factory orders for June. Economists predict that orders increased 1.0% during the month, compared with a 1.7% rise in May.\nWednesday 8/4\nSony Group,CVS Health, Kraft Heinz, SoftBank, General Motors, Progressive, Etsy, Electronic Arts, Western Digital, Uber Technologies, Roku,MGM Resorts International,Fox, and Re/Max Holdings are expected to host earnings calls.\nThe Bureau of Economic Analysis reports light-vehicle sales for July. Expectations call for a seasonally adjusted annual rate of 15.3 million vehicles, versus 15.4 million in June.\nThe ISM releases its Services PMI for July. Consensus estimate is for a 60.8 reading, compared with June’s 60.1.\nADP releases its National Employment report for July. Consensus estimate is for a 635,000 gain in nonfarm private-sector employment, following an increase of 692,000 in June.\nThursday 8/5\nZillow Group,Beyond Meat, Yelp, Wayfair, Kellogg,Bayer,HanesBrands, Moderna,Regeneron Pharmaceuticals,Switch,Cushman & Wakefield,ViacomCBS,Cigna,Duke Energy,Square,News Corp,and Siemensare expected to report financial results.\nFriday 8/6\nThe BLS releases the jobs report for July. Economists forecast a 800,000 rise in nonfarm payrolls, after an 850,000 gain in June. The unemployment rate is expected to edge down to 5.8% from 5.9%.\nDraftKings,Dominion Energy,Gannett,MGM Growth Properties,AMC Networks,Canopy Growth, Tripadvisor,Spectrum Brands Holdings,E.W. Scripps,Cinemark Holdings, and Manitowoc host conference calls to discuss financial results.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800691959,"gmtCreate":1627295769671,"gmtModify":1703486987532,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>any good news to lift up the price? Not even from CEO? Is there any new agreement/contract with other companies&nbsp;to expand the business?","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>any good news to lift up the price? Not even from CEO? Is there any new agreement/contract with other companies&nbsp;to expand the business?","text":"$ContextLogic Inc.(WISH)$any good news to lift up the price? Not even from CEO? Is there any new agreement/contract with other companies to expand the business?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/800691959","isVote":1,"tweetType":1,"viewCount":965,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145117386,"gmtCreate":1626196936145,"gmtModify":1703755403412,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SPCE\">$Virgin Galactic(SPCE)$</a>ideal price at level $30 to $35.","listText":"<a href=\"https://laohu8.com/S/SPCE\">$Virgin Galactic(SPCE)$</a>ideal price at level $30 to $35.","text":"$Virgin Galactic(SPCE)$ideal price at level $30 to $35.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/145117386","isVote":1,"tweetType":1,"viewCount":1063,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156606648,"gmtCreate":1625215315384,"gmtModify":1703738522244,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/156606648","repostId":"1106989513","repostType":4,"repost":{"id":"1106989513","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625213344,"share":"https://ttm.financial/m/news/1106989513?lang=&edition=fundamental","pubTime":"2021-07-02 16:09","market":"us","language":"en","title":"Marin software surged another 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1106989513","media":"Tiger Newspress","summary":"Marin software surged another 5% in premarket trading from yesterday's 40% surge.\n\nLast week, Marin ","content":"<p>Marin software surged another 5% in premarket trading&nbsp;from yesterday's 40% surge.</p>\n<p><img src=\"https://static.tigerbbs.com/0d3bd932aa1e45fe82c1b33252f7f8bc\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p>\n<p>Last week, Marin shares shot up after it said it had added the ability to manage Instacart advertisements to its flagship MarinOne platform.</p>\n<p>For the first quarter, Marin revenues totaled $6.3 million, a year-over-year increase of 27%, while earnings per share stood at minus 0.22.</p>\n<p>On a year-to-date basis, MRIN shares have shot up 782%. Early Tuesday, Marin topped the list of 10 trending streams as arranged by Stocktwits.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marin software surged another 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarin software surged another 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-02 16:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Marin software surged another 5% in premarket trading&nbsp;from yesterday's 40% surge.</p>\n<p><img src=\"https://static.tigerbbs.com/0d3bd932aa1e45fe82c1b33252f7f8bc\" tg-width=\"1302\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p>\n<p>Last week, Marin shares shot up after it said it had added the ability to manage Instacart advertisements to its flagship MarinOne platform.</p>\n<p>For the first quarter, Marin revenues totaled $6.3 million, a year-over-year increase of 27%, while earnings per share stood at minus 0.22.</p>\n<p>On a year-to-date basis, MRIN shares have shot up 782%. Early Tuesday, Marin topped the list of 10 trending streams as arranged by Stocktwits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRIN":"Marin Software Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106989513","content_text":"Marin software surged another 5% in premarket trading from yesterday's 40% surge.\n\nLast week, Marin shares shot up after it said it had added the ability to manage Instacart advertisements to its flagship MarinOne platform.\nFor the first quarter, Marin revenues totaled $6.3 million, a year-over-year increase of 27%, while earnings per share stood at minus 0.22.\nOn a year-to-date basis, MRIN shares have shot up 782%. Early Tuesday, Marin topped the list of 10 trending streams as arranged by Stocktwits.","news_type":1},"isVote":1,"tweetType":1,"viewCount":30,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882591370,"gmtCreate":1631703883590,"gmtModify":1676530613091,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882591370","repostId":"1133293397","repostType":4,"isVote":1,"tweetType":1,"viewCount":363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815141806,"gmtCreate":1630659906505,"gmtModify":1676530368688,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>like a coin that have two sides either long or short, it's depend on you how to anticipate...","listText":"<a href=\"https://laohu8.com/S/XELA\">$Exela Technologies, Inc.(XELA)$</a>like a coin that have two sides either long or short, it's depend on you how to anticipate...","text":"$Exela Technologies, Inc.(XELA)$like a coin that have two sides either long or short, it's depend on you how to anticipate...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/815141806","isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571209718541642","authorId":"3571209718541642","authorIdStr":"3571209718541642","name":"Tom_Jerry","avatar":"https://static.tigerbbs.com/5ce158ae76ab06ae07b990f57e8ced26","crmLevel":2,"crmLevelSwitch":0,"idStr":"3571209718541642"},"content":"everyone wanted to buy with green. If it didn't turn to your need, either hold or retrieve.","text":"everyone wanted to buy with green. If it didn't turn to your need, either hold or retrieve.","html":"everyone wanted to buy with green. If it didn't turn to your need, either hold or retrieve."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174094401,"gmtCreate":1627051773403,"gmtModify":1703483432402,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>stop loss order in placed, wish without wishes...","listText":"<a href=\"https://laohu8.com/S/WISH\">$ContextLogic Inc.(WISH)$</a>stop loss order in placed, wish without wishes...","text":"$ContextLogic Inc.(WISH)$stop loss order in placed, wish without wishes...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/174094401","isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172486917,"gmtCreate":1626973109039,"gmtModify":1703481751891,"author":{"id":"3586474323146945","authorId":"3586474323146945","authorIdStr":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IPA\">$Immunoprecise Antibodies Ltd(IPA)$</a>wow","listText":"<a href=\"https://laohu8.com/S/IPA\">$Immunoprecise Antibodies Ltd(IPA)$</a>wow","text":"$Immunoprecise Antibodies Ltd(IPA)$wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/172486917","isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}